[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23575
1. Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, Ajani JA, Swisher SG, Wu TT: Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol; 2007 Nov;31(11):1719-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.
  • Depth of invasion is one of the most important prognostic indicators in esophageal adenocarcinoma.
  • Unlike other regions of the gastrointestinal tract, the esophagus in Barrett metaplasia frequently develops duplication of the muscularis mucosae (MM), but this feature is underrecognized, and its effect on appropriate staging of superficially invasive adenocarcinoma is unclear.
  • We first randomly selected 50 esophageal resections for high-grade dysplasia or T1 adenocarcinoma in Barrett esophagus (BE) to evaluate the sensitivity and specificity of MM duplication for BE and its histologic characteristics, including percentage of the Barrett segment involved by MM duplication, origin of the duplicated muscle layer, and appearance of the tissue between duplicated MM.
  • Next, to study the clinical significance of MM duplication, we evaluated 30 resections for BE that had superficial adenocarcinoma confined to regions of duplicated MM.
  • Of 30 adenocarcinomas invading duplicated MM, 10 (33%) invaded only inner MM, 12 (40%) invaded the space between MM, and 8 (27%) invaded the outer MM.
  • These data show that MM duplication is a characteristic finding in BE, but it can pose difficulty in proper staging of superficial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology
  • [MeSH-minor] Adult. Aged. Esophagectomy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Dec;32(12):1913; author reply 1913-4 [18824891.001]
  • (PMID = 18059229.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Matsubara D, Morikawa T, Goto A, Nakajima J, Fukayama M, Niki T: Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis. Mod Pathol; 2009 Jun;22(6):776-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis.
  • We report here the presence of subepithelial myofibroblasts in pure bronchioloalveolar carcinoma and a subset of invasive lung adenocarcinoma.
  • To gain insight into their biological significance, we examined 116 surgically resected lung adenocarcinomas.
  • The resected tumors included 13 bronchioloalveolar carcinomas, 20 mixed type adenocarcinomas with bronchioloalveolar carcinoma components, 57 papillary adenocarcinomas, 22 solid adenocarcinomas with mucin, and 4 acinar adenocarcinomas.
  • In mixed adenocarcinomas with bronchioloalveolar carcinoma components, subepithelial myofibroblasts were present in the bronchioloalveolar carcinoma components, but scanty in the invasive areas, where stromal myofibroblasts emerged between the cancer cell nests.
  • Subepithelial myofibroblasts were retained, however, in the invasive areas of a subset of invasive adenocarcinomas.
  • A subset of invasive adenocarcinomas retains subepithelial myofibroblasts.
  • Analysis of subepithelial myofibroblasts may be helpful in identifying a subset of lung adenocarcinoma with excellent prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Fibroblasts / pathology. Lung Neoplasms / pathology. Myocytes, Smooth Muscle / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329939.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


Advertisement
4. Khunamornpong S, Thorner PS, Suprasert P, Siriaunkgul S: Clear-cell adenocarcinoma of the female genital tract: presence of hyaline stroma and tigroid background in various types of cytologic specimens. Diagn Cytopathol; 2005 Jun;32(6):336-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenocarcinoma of the female genital tract: presence of hyaline stroma and tigroid background in various types of cytologic specimens.
  • Hyaline basement membrane-like stromal material and tigroid background are distinctive cytologic features observed in Diff-Quik (DQ)- or Giemsa-stained smears of clear-cell adenocarcinoma (CCA) of the female genital tract.
  • However, it is uncertain how often these features are present in different types of cytologic specimens, and which type of preparation is optimal for this diagnosis.
  • We propose that scrape cytology offers the best approach for the intraoperative cytologic diagnosis of CCA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor. Hyalin
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Genital Neoplasms, Female. Humans. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880717.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Kobayashi Y, Yokose T, Kawamura K, Iwasaki S, Murata Y, Onuma S, Hasebe T, Nagai K, Sasaki S, Ochiai A: Cytologic factors associated with prognosis in patients with peripheral adenocarcinoma of the lung measuring 3 cm or less in greatest dimension. Cancer; 2005 Feb 25;105(1):44-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic factors associated with prognosis in patients with peripheral adenocarcinoma of the lung measuring 3 cm or less in greatest dimension.
  • BACKGROUND: Recently, peripheral lung adenocarcinomas (PLA) measuring < or = 3 cm in greatest dimension often have been diagnosed using diagnostic radiology.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 American Cancer Society
  • (PMID = 15529400.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Kim SS, Nam JH, Kim SM, Choi YD, Lee JH: Peritoneal melanosis associated with mucinous cystadenoma of the ovary and adenocarcinoma of the colon. Int J Gynecol Pathol; 2010 Mar;29(2):113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal melanosis associated with mucinous cystadenoma of the ovary and adenocarcinoma of the colon.
  • In this paper, we describe a case of peritoneal melanosis associated with a mucinous cystadenoma on an ovary and adenocarcinoma in the colon of 68-year-old women.
  • [MeSH-major] Adenocarcinoma / pathology. Cystadenoma, Mucinous / pathology. Melanosis / pathology. Ovarian Neoplasms / pathology. Peritoneum / pathology. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173496.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer; 2008 Jan;59(1):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
  • However, there is no clear data demonstrating whether such molecular changes of EGFR per se can affect the clinical outcome of early stage cancer after surgical resection.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • Whereas KRAS mutation was a poor prognostic factor, EGFR mutation was not, and its presence per se did not affect the clinical outcome of early lung cancer after surgical resection.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904685.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


8. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • We suggest that this case could be an argument for recommending regular follow-up for women with ectopic ureter for detecting malignant transformation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


9. Soreide K, Janssen EA, Körner H, Baak JP: Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol; 2006 Jun;209(2):147-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, colorectal cancers with trypsin expression have a poor prognosis and shorter disease-free survival.
  • MMPs may play a role in both conversion from adenoma to carcinoma, and in the initiation of invasion and metastasis.
  • [MeSH-minor] Adenoma / chemistry. Adenoma / genetics. Adenoma / physiopathology. Cell Division / genetics. Cell Division / physiology. Disease Progression. Humans. Matrix Metalloproteinases / metabolism. Models, Biological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / genetics. Neoplasm Metastasis / physiopathology. Prostaglandins / biosynthesis. Receptor, PAR-2 / metabolism. Receptors, Proteinase-Activated / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16691544.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Prostaglandins; 0 / Receptor, PAR-2; 0 / Receptors, Proteinase-Activated; EC 3.4.21.4 / Trypsin; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 105
  •  go-up   go-down


10. Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P: Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res; 2008 Jul 1;14(13):4096-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers.
  • PURPOSE: There are major differences affecting genes in adenocarcinomas in ever and never smokers.
  • EXPERIMENTAL DESIGN: Expression of activated extracellular signal-regulated kinases, c-Jun NH(2)-terminal kinases, and P38 enzymes (pP38) were evaluated by means of immunohistochemistry in 188 chemonaïve patients with surgically resected lung adenocarcinoma.
  • Cell viability of the lung adenocarcinoma cell line HCC827 was studied after treatment with cisplatin or the P38 MAPK inhibitor SB 203580.
  • Never smokers were 10.5 times (95% CI, 3.5-31.5) more likely to express high pP38 levels after adjustment for variables linked to smoking status, including age, sex, and histologic subtype.
  • CONCLUSIONS: Life-long nonsmoking is associated with high activated P38 levels in patients with lung adenocarcinoma.
  • Activated P38 can contribute to the viability of adenocarcinoma cells in never smokers, but is not predictive for overall survival.
  • [MeSH-major] Adenocarcinoma / enzymology. Gene Expression Regulation, Neoplastic. Lung Neoplasms / enzymology. Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18593986.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


11. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Capelozzi VL: Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer; 2009 Apr;64(1):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma.
  • METHODS: We assessed TTF-1 and MMP-9 tumor expression by immunohistochemistry in 51 patients with lung adenocarcinoma, stage IIIB or IV, treated with platinum regimens.
  • CONCLUSION: TTF-1 and MMP-9 tumor expression as detected by immunohistochemistry may allow identification of different, clinically meaningful, prognostic groups of advanced lung adenocarcinoma patients treated with platinum regimens.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801593.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


12. Shah SS, Adelson M, Mazur MT: Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. Int J Gynecol Pathol; 2008 Jul;27(3):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases.
  • Adenocarcinoma in situ rarely occurs in vulvar papillary hidradenoma.
  • We encountered 2 cases of adenocarcinoma in situ arising in a papillary hidradenoma of the vulva.
  • On microscopic examination, the tumors showed focal features of benign hidradenoma at the periphery with transitions into areas of increasing cytologic atypia that fulfilled criteria for adenocarcinoma in situ similar to that seen in the breast.
  • Both lesions show areas strongly immunoreactive for mammaglobin and gross cystic disease fluid protein 15 as well as estrogen and progesterone receptor protein in 1 case.
  • The fact that these tumors displayed morphologic and immunohistochemical features that resembled ductal carcinoma in situ of the breast demonstrates the close homology between papillary hidradenoma and breast epithelium.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Carcinoma in Situ / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Disease Progression. Female. Humans

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580327.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hammoud ZT, Mechref Y, Hussein A, Bekesova S, Zhang M, Kesler KA, Novotny MV: Comparative glycomic profiling in esophageal adenocarcinoma. J Thorac Cardiovasc Surg; 2010 May;139(5):1216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative glycomic profiling in esophageal adenocarcinoma.
  • We performed glycomic profiling of serum from patients with no known disease, Barrett's without dysplasia, with high-grade dysplasia, and with esophageal adenocarcinoma in an attempt to delineate distinct differences in glycosylation among these groups.
  • METHODS: Serum samples from patients with Barrett's metaplasia (N = 5), high-grade dysplasia (N = 11), and esophageal adenocarcinoma (N = 50) were collected; samples from 18 healthy volunteers were used as control.
  • CONCLUSION: We demonstrated that comparative glycomic profiling of esophageal adenocarcinoma reveals a subset of glycans that can be selected as candidate biomarkers.
  • These markers can differentiate normal from high-grade dysplasia, normal from esophageal adenocarcinoma, and high-grade dysplasia from esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Barrett Esophagus / blood. Esophageal Neoplasms / blood. Glycomics. Polysaccharides / blood. Precancerous Conditions / blood. Protein Processing, Post-Translational
  • [MeSH-minor] Biomarkers / blood. Glycosylation. Humans. Metaplasia. Neoplasm Staging. Principal Component Analysis. Reproducibility of Results. Solid Phase Extraction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20412957.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Polysaccharides
  •  go-up   go-down


14. di Pietro M, Peters CJ, Fitzgerald RC: Clinical puzzle: Barrett's oesophagus. Dis Model Mech; 2008 Jul-Aug;1(1):26-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of oesophageal adenocarcinoma has increased dramatically in the Western world over the past two decades.
  • Owing to its dismal 5-year prognosis in advanced stages, early diagnosis is required in order to improve survival rates.
  • Barrett's oesophagus (Barrett's) has been recognised as a pre-cancerous condition generally associated with chronic and severe gastro-oesophageal reflux disease (GORD).
  • Clinical challenges include finding cost-effective ways to identify patients with Barrett's, stratifying them according to their cancer risk and improving the diagnostic potential of endoscopic sampling.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers / analysis. Cell Transformation, Neoplastic. Disease Progression. Early Diagnosis. Genetic Predisposition to Disease. Humans. Models, Biological

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Dec;129(6):2125-6; author reply 2126 [16344087.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):735-42 [16556175.001]
  • [Cites] Gut. 2006 Aug;55(8):1078-83 [16469795.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):423-31 [17064856.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Histopathology. 2007 Jun;50(7):920-7 [17543082.001]
  • [Cites] Gut. 2007 Jul;56(7):906-17 [17185354.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2788-803 [17974918.001]
  • [Cites] Gut. 2008 Feb;57(2):167-72 [17965067.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):89-94 [10767821.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Endoscopy. 2001 May;33(5):391-400 [11396755.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jul;22(1):1-6 [12103364.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):60-6 [12109857.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):457-9 [8781742.001]
  • [Cites] Br J Clin Pract. 1996 Jul-Aug;50(5):245-8 [8794600.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jan;34(1):46-52 [9542635.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):730-9 [15971196.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):889-907 [16338648.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • (PMID = 19048049.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2561971
  •  go-up   go-down


15. Dembinski JL, Krauss S: Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis; 2009;26(7):611-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
  • Evidence suggests that multiple tumors, including pancreatic adenocarcinoma, display heterogeneity in parameters that are critical for tumor formation, progression and metastasis.
  • In this study, a particular focus was put on identifying a subpopulation of stem cell-like, slow cycling tumor cells in a pancreas adenocarcinoma cell lines.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplastic Stem Cells / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antimetabolites, Antineoplastic / administration & dosage. Cell Line, Tumor. Female. Flow Cytometry. Fluorouracil / administration & dosage. Hedgehog Proteins / metabolism. Humans. Mice. Mice, SCID. Neoplasm Metastasis. Polymerase Chain Reaction. Receptor, Epidermal Growth Factor / metabolism. Transforming Growth Factor beta / metabolism


16. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL: PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol; 2009 May;174(5):1869-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
  • Prostate intraepithelial neoplasia lesions develop in mice with Pten heterozygosity, but disease progression has been reported only in combination with either other tumor suppressor gene alterations or the conditional inactivation of both Pten alleles in prostate epithelial cells.
  • We report that on a C57BL/6 background, in contrast to previous studies on mixed 129 genetic backgrounds, Pten locus heterozygosity is fully penetrant for the development of prostate adenocarcinoma.
  • Grossly observable tumors were detected at 6 months of age, and, by 10 to 12 months, 100% of examined mice developed adenocarcinoma of the anterior prostate.
  • PI3K activation occurred early in prostate intraepithelial neoplasia lesion formation in these animals, consistent with loss of PTEN function, and contributed to the etiology of tumors that developed in Pten(+/-) mice.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):279-89 [16636147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17771-6 [17978178.001]
  • [Cites] Genome Biol. 2007;8(6):R117 [17577413.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6 [18268330.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2223-32 [18381428.001]
  • [Cites] Genes Dev. 2008 Aug 15;22(16):2172-7 [18708577.001]
  • [Cites] Cell. 2000 Feb 18;100(4):387-90 [10693755.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2410-34 [11018010.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):222-4 [11175795.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):929-32 [11265178.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8 [11553783.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2999-3004 [12036903.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6141-5 [12414639.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3886-90 [12873978.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):225-54 [15163300.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4800-3 [7585509.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4997-5000 [9371490.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):204-9 [9443392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 [9560261.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1206-11 [10096549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):75-7 [10343618.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):19-24 [15624019.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2825-31 [15805283.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5730-9 [15994948.001]
  • [Cites] Genes Dev. 2005 Aug 1;19(15):1779-86 [16027168.001]
  • [Cites] Genes Dev. 2005 Aug 1;19(15):1773-8 [16027169.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7455-64 [16288292.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2188-94 [16489020.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6492-6 [16818619.001]
  • (PMID = 19395652.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NIEHS NIH HHS / ES / ES007784; United States / NCI NIH HHS / CA / P50 CA090270; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA90270; United States / NCI NIH HHS / CA / P30 CA16672-30; United States / NIEHS NIH HHS / ES / P30 ES007784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2671275
  •  go-up   go-down


17. Miki D, Kubo M, Takahashi A, Yoon KA, Kim J, Lee GK, Zo JI, Lee JS, Hosono N, Morizono T, Tsunoda T, Kamatani N, Chayama K, Takahashi T, Inazawa J, Nakamura Y, Daigo Y: Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet; 2010 Oct;42(10):893-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.
  • To identify genetic factors that modify the risk of lung adenocarcinoma, we conducted a genome-wide association study in a Japanese cohort, with replication in two independent studies in Japanese and Korean individuals, in a total of 2,098 lung adenocarcinoma cases and 11,048 controls.
  • The combined analyses identified two susceptibility loci for lung adenocarcinoma: TERT (rs2736100, combined P = 2.91 × 10⁻¹¹), odds ratio (OR) = 1.27) and TP63 (rs10937405, combined P = 7.26 × 10⁻¹²), OR = 1.31).
  • Our results suggest that genetic variation in TP63 may influence susceptibility to lung adenocarcinoma in East Asian populations.
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Predisposition to Disease. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Trans-Activators / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871597.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


18. Hannuna KY, Putignani L, Silvestri E, Pisa R, Angioli R, Signore F: Incidental endometrial adenocarcinoma in early pregnancy: a case report and review of the literature. Int J Gynecol Cancer; 2009 Dec;19(9):1580-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental endometrial adenocarcinoma in early pregnancy: a case report and review of the literature.
  • Endometrial cancer is the most common neoplasia of the female reproductive system, with the highest incidence among uterine malignancies, and is rarely associated with pregnancy.
  • A 39-year-old woman, gravida 4, para 2, was diagnosed with a focal, well- to moderately differentiated endometrial adenocarcinoma (International Federation of Gynecology and Obstetrics stage IA and grades G1 and G2) after dilatation and curettage (D&C) for a spontaneous abortion.
  • The patient underwent progestational therapy and follow-up hysteroscopies and D&C to preserve fertility; she is alive and well 18 months after diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Cancer. 2010 Feb;20(2):313. Yael, Hannuna Karen [corrected to Hannuna, Karen Yael]; Lorenza, Putignani [corrected to Putignani, Lorenza]; Evelina, Silvestri [corrected to Silvestri, Evelina]; Roberto, Pisa [corrected to Pisa, Roberto]; Roberto, Angioli [corrected to Angioli, Roberto]; Fabrizio, Signore [corrected to Signore, Fabrizio]
  • (PMID = 19955941.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


19. Makis W, Abikhzer G, Rush C: Hypertrophic pulmonary osteoarthropathy diagnosed by FDG PET-CT in a patient with lung adenocarcinoma. Clin Nucl Med; 2009 Sep;34(9):625-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic pulmonary osteoarthropathy diagnosed by FDG PET-CT in a patient with lung adenocarcinoma.
  • A 52-year-old man had a positron emission tomography computed tomography (PET-CT) scan for staging of a biopsy proven lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Fluorodeoxyglucose F18. Lung Neoplasms / complications. Osteoarthropathy, Secondary Hypertrophic / complications. Osteoarthropathy, Secondary Hypertrophic / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692831.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ: Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):727-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma has increased in recent years, and Barrett's esophagus is a recognized risk factor.
  • Increased expression of these enzymes has been found in esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
  • In a population-based case-control study, we examined associations of the COX-2 8473 T>C and iNOS Ser(608) Leu (C>T) polymorphisms with risk of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
  • Genomic DNA was extracted from blood samples collected from cases of esophageal adenocarcinoma (n = 210), Barrett's esophagus (n = 212), and reflux esophagitis (n = 230) and normal population controls frequency matched for age and sex (n = 248).
  • The presence of at least one COX-2 8473 C allele was associated with a significantly increased risk of esophageal adenocarcinoma (adjusted odds ratio, 1.58; 95% confidence interval, 1.04-2.40).
  • Our study suggests that the COX-2 8473 C allele is a potential genetic marker for susceptibility to esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Barrett Esophagus / enzymology. Barrett Esophagus / genetics. Cyclooxygenase 2 / genetics. Esophageal Neoplasms / enzymology. Esophageal Neoplasms / genetics. Esophagitis, Peptic / enzymology. Esophagitis, Peptic / genetics. Nitric Oxide Synthase Type II / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349295.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


21. Pavelić J, Radaković B, Pavelić K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol; 2007 Jun;105(3):727-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma.
  • OBJECTIVE: To investigate the consequences of IGF proteins dysfunction in development of endometrial adenocarcinomas.
  • METHODS: The expression of IGF 2 and IGF 1R was correlated with the expression of IGF 2R and apoptosis rate in 59 human endometrial adenocarcinomas, 10 endometrial hyperplasias and 7 normal tissues.
  • The presence of mutations in the IGF 2R gene was followed in 46 adenocarcinomas.
  • RESULTS: The expression of IGF 2 and IGF 1R was much higher in malignant tissue of stages III and IV than in tumors of stages I and II and normal or hyperplastic endometrium.
  • Eight adenocarcinomas expressed biallelic mutation of the IGF 2R gene.
  • CONCLUSION: Our data suggest that IGF 1, IGF 2 and their receptors are involved in the progression of endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Mannosephosphates / biosynthesis. Proteins / metabolism. Receptor, IGF Type 1 / biosynthesis. Receptor, IGF Type 2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17399767.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / IGF2 protein, human; 0 / Mannosephosphates; 0 / Proteins; 0 / RNA, Messenger; 0 / Receptor, IGF Type 2; 3672-15-9 / mannose-6-phosphate; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


22. Jordan KW, Nordenstam J, Lauwers GY, Rothenberger DA, Alavi K, Garwood M, Cheng LL: Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum; 2009 Mar;52(3):520-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy.
  • PURPOSE: This study was designed to test whether metabolic characterization of intact, unaltered human rectal adenocarcinoma specimens is possible using the high-resolution magic angle spinning proton (1H) magnetic resonance spectroscopy technique.
  • Multiple biopsies of macroscopically malignant rectal tumors and benign rectal mucosa were obtained from each patient for a total of 14 malignant and 9 benign samples.
  • RESULTS: Metabolomic profiles represented by principle components of metabolites measured from spectra differentiated between malignant and benign samples and correlated with the volume percent of cancer (P = 0.0065 and P = 0.02, respectively) and benign epithelium (P = 0.0051 and P = 0.0255, respectively), and with volume percent of stroma, and inflammation.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):10-5 [11786756.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):653-8 [8916014.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Radiology. 1999 Apr;211(1):215-22 [10189474.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3030-4 [15833828.001]
  • [Cites] NMR Biomed. 2006 Feb;19(1):30-40 [16229059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • (PMID = 19333056.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115746-03; United States / NCI NIH HHS / CA / R01 CA095624; United States / NCI NIH HHS / CA / CA095624; United States / NCI NIH HHS / CA / CA115746; United States / NCI NIH HHS / CA / CA095624-04; United States / NCI NIH HHS / CA / R01 CA115746; United States / NCI NIH HHS / CA / R01 CA095624-04; United States / NCI NIH HHS / CA / R01 CA115746-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS119443; NLM/ PMC2720561
  •  go-up   go-down


23. Uncu D, Ozdemir NY, Aksoy S, Abali H, Oksuzoglu BC, Budakoglu B, Yildiz R, Aslan N, Zengin N: Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. Asian Pac J Cancer Prev; 2010;11(6):1493-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
  • PATIENTS AND METHODS: Between May 2005 and Dec 2008, 65 curatively resected gastric and gastroesophageal junction adenocarcinoma patients (stage III in 38 and stage IV M0 in 27) received chemotherapy including 50 mg/m2 cisplatin, 200 mg/m2 iv folinic acid, 5-FU 400 mg/m2 iv bolus followed by 5-FU 1600 mg/m2 46h-continuous infusion (CFF) bi-weekly.
  • Median disease free survival was 18 months (95% CI:13.9-22.0) and median overall survival was 19 months (95% CI:15.2-22.8).
  • CONCLUSION: Bi-weekly CFF chemotherapy followed by continuous 5-FU infusion during radiotherapy is an effective and tolerable regimen for locally advanced operated gastric and gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction. Neoplasm Recurrence, Local / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338186.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Piessen G, Wacrenier A, Briez N, Triboulet JP, Van Seuningen I, Mariette C: Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma. J Clin Pathol; 2009 Dec;62(12):1144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma.
  • AIMS: To study the expression of MUC1 and MUC4 mucins in Barrett-associated oesophageal adenocarcinoma and coexisting lesions of the carcinogenic sequence (normal mucosa, metaplasia, dysplasia) if present, and to investigate their prognostic significance.
  • METHODS: The expression profiles of MUC1 and MUC4 were investigated by immunohistochemistry in tissue samples obtained from consecutive patients with primary surgically resected lower third oesophageal adenocarcinoma (OA) between 1997 and 2002.
  • MUC1 and MUC4 were expressed in 52 and 41 of the 52 patients with adenocarcinoma (100% and 78%), respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Mucin-1 / metabolism. Mucin-4 / metabolism
  • [MeSH-minor] Disease Progression. Follow-Up Studies. Humans. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946103.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC4 protein, human; 0 / Mucin-1; 0 / Mucin-4; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Meng YH, Li S, Hu T, Ma D, Lu YP, Wang H: [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma]. Chin J Cancer; 2010 Jan;29(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
  • METHODS: Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.
  • RESULTS: The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05).
  • There was no significant difference of 2-year overall and disease-free survival rates between the two groups (P>0.05).
  • There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Pelvic Neoplasms / secondary. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden


26. Ilias EJ, Malheiros CA, Kassab P, Castro OA: [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma]. Rev Assoc Med Bras (1992); 2006 Jul-Aug;52(4):270-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma].
  • [Transliterated title] Linfadenectomia no adenocarcinoma gástrico.
  • c) D2 lymphadenectomy avoided residual lymph node disease in almost half of the patients operated.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Lymph Node Excision / methods. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual. Practice Guidelines as Topic. Prospective Studies. Societies, Medical

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967148.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


27. Euanorasetr C, Lertsithichai P: Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy. Gastric Cancer; 2007;10(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy.
  • BACKGROUND: The aim of the present study was to determine the prognostic significance of peritoneal washing cytology (PWC) among Thai patients with gastric adenocarcinoma.
  • METHODS: Medical charts of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005 were reviewed.
  • CONCLUSION: Gastric adenocarcinoma with positive PWC should be considered stage IV disease.
  • PWC should be included in the staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Neoplasms / pathology. Peritoneum / cytology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Gastric Cancer. 2001;4(1):27-33 [11706624.001]
  • [Cites] Surg Gynecol Obstet. 1961 Apr;112:469-74 [13772295.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):71-5 [9808508.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7374-7 [16437646.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):170-6, discussion 176-7 [16455447.001]
  • [Cites] Surg Today. 1999;29(2):111-5 [10030734.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):611-7 [9179118.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] Surg Today. 2005;35(11):919-24 [16249844.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):92-100 [10813130.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):44-7 [2049751.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):1-7 [11957063.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Surg Oncol. 1992 Oct;1(5):341-6 [1341269.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):372-9 [9527060.001]
  • [Cites] Acta Cytol. 1978 Jul-Aug;22(4):225-9 [281825.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):103-7 [10449681.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):520-4 [10027323.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1131-4 [16086213.001]
  • [Cites] Cancer. 1979 Oct;44(4):1476-80 [498022.001]
  • [Cites] Gastric Cancer. 2005;8(4):228-37 [16328597.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):339-41 [15843872.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1419-23 [14532985.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):411-5 [9718170.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):450-4; discussion 455 [7639005.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):437-42 [2160771.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • (PMID = 17334713.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC: Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila); 2009 Feb;2(2):114-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
  • We examined alterations in the p53 tumor suppressor gene and the ras and HER-2/neu oncogenes in chicken ovarian cancers to determine if these tumors have genetic alterations similar to those in human ovarian adenocarcinomas.
  • Immunohistochemical staining for the HER-2/neu oncogene was done on a subset of avian ovarian and oviductal adenocarcinomas.
  • Significant HER-2/neu staining was noted in 10 of 19 ovarian adenocarcinomas but in only 1 of 17 oviductal adenocarcinomas.
  • Similar to human ovarian cancers, p53 alterations are common in chicken ovarian adenocarcinomas and correlate with the number of lifetime ovulations.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras / genetics. Mutation / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / metabolism. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / genetics. Chickens / genetics. Chickens / metabolism. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Oviducts / metabolism. Oviducts / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Prev Res (Phila). 2009 Feb;2(2):97-9 [19174576.001]
  • [ErratumIn] Cancer Prev Res (Phila Pa). 2009 Mar;2(3):283
  • (PMID = 19174584.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01 CN005114
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


29. Kato T, Nakashima M, Yoshimura K, Imao M, Goto H, Yasuda S, Sano K: [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2005 Nov;43(11):700-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
  • CASE: A 40-year-old man was given a diagnosis of adenocarcinoma of lung (c-T2N3M1).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


30. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, Ellis LM, Gallick GE: Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res; 2005 May 1;65(9):3664-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors.
  • Expression of NRP-1 has been shown in many human tumors, including pancreatic adenocarcinomas.
  • To discern the regulatory role(s) of NRP-1 in pancreatic adenocarcinoma that lack these coreceptors, we overexpressed both full-length NRP-1 and a deletion form of NRP-1 that does not interact with semaphorin or VEGF.
  • [MeSH-major] Adenocarcinoma / pathology. Nerve Tissue Proteins / deficiency. Neuropilin-1 / physiology. Pancreatic Neoplasms / pathology. Receptors, Cell Surface / deficiency. Vascular Endothelial Growth Factor Receptor-2 / deficiency

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867361.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01 CA65527; United States / PHS HHS / / T-32 09599; United States / NCI NIH HHS / CA / U54 CA 090810-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / PLXNA1 protein, human; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 0 / SEMA3A protein, human; 0 / Semaphorin-3A; 0 / Vascular Endothelial Growth Factor A; 144713-63-3 / Neuropilin-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


31. Chang MY, Yu YP, Tsai JR, Sheu CC, Chong IW, Lin SR: Combined oligonucleotide microarray-bioinformatics and constructed membrane arrays to analyze the biological pathways in the carcinogenesis of human lung adenocarcinoma. Oncol Rep; 2007 Sep;18(3):569-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined oligonucleotide microarray-bioinformatics and constructed membrane arrays to analyze the biological pathways in the carcinogenesis of human lung adenocarcinoma.
  • The results revealed that 1,396 genes were up-regulated and 1,965 were down-regulated in lung adenocarcinoma carcinogenesis.
  • Furthermore, we constructed a membrane array, consisting of 51 up-regulated genes in lung adenocarcinoma, in order to verify the biological pathways involved in the carcinogenesis of lung cancer.
  • The analysis of 45 lung adenocarcinoma tissue specimens demonstrated that the genes involved in these three biological pathways had high rates of overexpression.
  • Out of the 51 genes, 17 genes were demonstrated to be overexpressed in all 45 lung adenocarcinoma tissues compared to the paired normal lung tissues.
  • These findings could have implications in understanding the process of lung adenocarcinoma carcinogenesis.
  • Moreover, our developed membrane arrays could be a potentially feasible and promising tool in clinical practice for analyzing the molecular mechanisms of lung adenocarcinoma carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Base Sequence. Computational Biology. Down-Regulation. Genomics. Humans. Molecular Sequence Data. Neoplasm Proteins / genetics. Oligonucleotide Probes. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671703.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oligonucleotide Probes
  •  go-up   go-down


32. Nishi M, Abe Y, Tomii Y, Tsukamoto H, Kijima H, Yamazaki H, Ohnishi Y, Iwasaki M, Inoue H, Ueyama Y, Nakamura M: Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol; 2005 Jun;26(6):1517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma.
  • This study aims to clear the clinicopathological characteristics of VEGF189 in the pulmonary adenocarcinoma.
  • We finely and quantitatively examined the expression of VEGF-A isoforms (VEGF121, VEGF165 and VEGF189) by real-time polymerase chain reaction in a total of 100 pulmonary adenocarcinomas resected by surgical operation.
  • All the pulmonary adenocarcinomas showed significant expression of VEGF-A.
  • Twenty-two cases with the adenocarcinomas overexpressing VEGF-A significantly showed earlier postoperative relapse and poorer prognosis between 5- to 15-year periods (p = 0.0093 and p = 0.0240, Kaplan Meier, log-rank test).
  • The expression levels of VEGF189 increased in 13% of the pulmonary adenocarcinoma.
  • The cellular binding isoform VEGF189 confers pulmonary adenocarcinoma patients with poorer prognosis with distant metastasis via blood flow.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Vascular Endothelial Growth Factor A / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870864.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


33. Nagano K, Umeda Y, Senoh H, Gotoh K, Arito H, Yamamoto S, Matsushima T: Carcinogenicity and chronic toxicity in rats and mice exposed by inhalation to 1,2-dichloroethane for two years. J Occup Health; 2006 Nov;48(6):424-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 2-yr exposure to DCE produced a dose-dependent increase in incidences of benign and malignant tumors, including subcutaneous fibroma, mammary gland fibroadenoma and peritoneal mesothelioma in male rats; subcutaneous fibroma and mammary gland adenoma, fibroadenoma and adenocarcinoma in female rats; and bronchiolo-alveolar adenoma and carcinoma, endometrial stromal polyp, mammary gland adenocarcinoma and hepatocellular adenoma in female mice.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. 1,2-DICHLOROETHANE .
  • Hazardous Substances Data Bank. DICHLOROETHANE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179635.001).
  • [ISSN] 1341-9145
  • [Journal-full-title] Journal of occupational health
  • [ISO-abbreviation] J Occup Health
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Ethylene Dichlorides; 55163IJI47 / ethylene dichloride
  •  go-up   go-down


34. Bull LM, White DL, Bray M, Nurgalieva Z, El-Serag HB: Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus; 2009;22(7):571-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.
  • Although several studies have examined the association between phase I/II enzyme polymorphisms and esophageal adenocarcinoma (EAC) and/or Barrett's esophagus (BE), their overall findings remain unclear.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):421-8 [7516776.001]
  • [Cites] Chest Surg Clin N Am. 1994 May;4(2):227-40 [8049993.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Carcinogenesis. 1994 Dec;15(12):2961-3 [8001264.001]
  • [Cites] Pharmacogenetics. 1994 Oct;4(5):242-6 [7894496.001]
  • [Cites] Eur J Cancer. 1994;30A(13):1921-35 [7734203.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5226-9 [7585580.001]
  • [Cites] Biochem J. 1995 Dec 15;312 ( Pt 3):713-6 [8554510.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3941-7 [8752161.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Carcinogenesis. 1996 Sep;17(9):1919-22 [8824514.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4965-9 [8895751.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10004-12 [9092542.001]
  • [Cites] Environ Health Perspect. 1997 Jun;105 Suppl 4:791-9 [9255563.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):852-7 [9307183.001]
  • [Cites] Br J Cancer. 1997;76(7):852-4 [9328142.001]
  • [Cites] Carcinogenesis. 1998 Mar;19(3):433-6 [9525277.001]
  • [Cites] Pharmacogenetics. 1998 Aug;8(4):299-304 [9731716.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):517-20 [9761122.001]
  • [Cites] Dis Esophagus. 2006;19(6):477-81 [17069592.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):423-31 [17064856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):178-81 [17220350.001]
  • [Cites] J Hum Genet. 2007;52(6):527-34 [17476458.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1323-8 [17277236.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Cancer Detect Prev. 2007;31(3):233-6 [17646057.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1643-58 [17674367.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):168-71 [10408710.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1013-8 [9829710.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):586-9 [9973204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):233-9 [10090301.001]
  • [Cites] Pharmacogenetics. 1999 Feb;9(1):113-21 [10208650.001]
  • [Cites] Pharmacogenetics. 1999 Apr;9(2):251-6 [10376772.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3389-93 [15526353.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Aug;25(8):731 [15555408.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):506-8 [15455349.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Oct;25(10):898-901 [15631753.001]
  • [Cites] Genet Med. 2005 Jan;7(1):13-20 [15654223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Front Biosci. 2005;10:1440-61 [15769636.001]
  • [Cites] World J Gastroenterol. 2005 May 7;11(17):2531-8 [15849806.001]
  • [Cites] J Clin Epidemiol. 2005 Jun;58(6):543-9 [15878467.001]
  • [Cites] Genet Med. 2005 Sep;7(7):463-78 [16170238.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1315-23 [16214603.001]
  • [Cites] Epidemiology. 2006 Jan;17(1):89-99 [16357600.001]
  • [Cites] Cell Biol Toxicol. 2006 Mar;22(2):73-80 [16532285.001]
  • [Cites] Cancer Detect Prev. 2006;30(2):144-51 [16638627.001]
  • [Cites] Cancer Lett. 2006 Jun 18;237(2):281-8 [16029924.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 1;170(1):76-7 [16965961.001]
  • [Cites] Cancer Lett. 2006 Oct 8;242(1):60-7 [16338071.001]
  • [Cites] Dis Esophagus. 2006;19(6):425-32 [17069584.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 1;58(11):1759-64 [10571250.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):397-404 [10581024.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28 [10667460.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):534-6 [10676631.001]
  • [Cites] JAMA. 2000 Apr 19;283(15):2008-12 [10789670.001]
  • [Cites] Pharmacogenetics. 2000 Apr;10(3):225-32 [10803678.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):458-64 [11008209.001]
  • [Cites] Carcinogenesis. 2000 Oct;21(10):1813-9 [11023538.001]
  • [Cites] Free Radic Biol Med. 2000 Aug;29(3-4):254-62 [11035254.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):258-62 [11071881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):785-91 [11440964.001]
  • [Cites] Am J Epidemiol. 2001 Jul 15;154(2):95-105 [11447041.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):29-34 [11815398.001]
  • [Cites] World J Gastroenterol. 2002 Feb;8(1):49-53 [11833070.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):249-60 [12115538.001]
  • [Cites] Biomarkers. 2002 May-Jun;7(3):230-41 [12141066.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1343-50 [12151353.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Aug;26(8 Suppl):15S-19S [12198369.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:65-77 [12351146.001]
  • [Cites] Scand J Gastroenterol. 2002 Dec;37(12):1359-65 [12523583.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):139-46 [12670526.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):905-9 [12771035.001]
  • [Cites] Clin Biochem. 2003 Jun;36(4):283-8 [12810157.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):381-6 [14506737.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1509-17 [14693745.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):119-25 [14726165.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Apr;25(4):341-5 [15231206.001]
  • [Cites] Asian Pac J Cancer Prev. 2004 Apr-Jun;5(2):133-8 [15244514.001]
  • [Cites] Biochem Pharmacol. 1979;28(2):171-6 [426831.001]
  • [Cites] Am J Hum Genet. 1981 Jan;33(1):36-43 [7468592.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Jun 28;177(3):1252-7 [1676262.001]
  • [Cites] Biochem J. 1992 Feb 15;282 ( Pt 1):305-6 [1540145.001]
  • [Cites] Pharmacogenetics. 1993 Jun;3(3):150-8 [8334439.001]
  • [Cites] Biochem J. 1994 Feb 1;297 ( Pt 3):441-5 [8110178.001]
  • (PMID = 19222528.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K01 DK081736
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  • [Other-IDs] NLM/ NIHMS565747; NLM/ PMC4018839
  •  go-up   go-down


35. Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW: Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology; 2006 Jan;67(1):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
  • OBJECTIVES: To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease.
  • CONCLUSIONS: Approximately 47% of men with a diagnosis of Gleason pattern 4 + 3 on needle biopsy are downgraded at radical prostatectomy and will have biochemical prostate-specific antigen recurrence-free outcomes similar to patients originally diagnosed with Gleason pattern 3 + 4 adenocarcinoma.
  • This group of patients may benefit from definitive treatment such as radical prostatectomy for management of their disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / epidemiology. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413345.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA58235
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. Cioffi U, De Simone M, Ferrero S, Ciulla MM, Lemos A, Avesani EC: Synchronous adenocarcinoma and carcinoid tumor of the terminal ileum in a Crohn's disease patient. BMC Cancer; 2005;5:157
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous adenocarcinoma and carcinoid tumor of the terminal ileum in a Crohn's disease patient.
  • BACKGROUND: Several malignancies have been described in association with inflammatory bowel diseases, the most common being adenocarcinoma.
  • Carcinoid tumor and Crohn disease has also been previously reported, however the coexistence of both neoplasms is quite rare and the clinical diagnosis is very difficult.
  • Here we report what we believe to be the fourth case of a mixed adenocarcinoid tumor coexisting with Crohn's disease.
  • CONCLUSION: Carcinoid tumor should be suspected in elderly patients with Crohn's disease presenting with intestinal obstruction and laparotomy should be considered to exclude malignancy.
  • [MeSH-major] Adenocarcinoma / complications. Carcinoid Tumor / complications. Crohn Disease / complications. Ileal Neoplasms / complications. Neoplasms, Second Primary / diagnosis


37. Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie SX, Berkland C, Tamura M: Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther; 2010 Feb;9(4):277-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells.
  • Thus, the aim of this study was to explore the anti-cancer effect of AT 2 over-expression on lung adenocarcinoma cells in vitro using adenoviral (Ad), FuGENE, and nanoparticle vectors.
  • Ad-AT 2 significantly attenuated multiple human lung cancer cell growth (A549 and H358) as compared to the control viral vector, Ad-LacZ, when cell viability was examined by direct cell count.
  • These results indicate that AT 2 over-expression effectively attenuates growth of lung adenocarcinoma cells through intrinsic apoptosis.
  • Our results also suggest that PLGA nanoparticles can be used as an efficient gene delivery vector for lung adenocarcinoma targeted therapy.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Mar 31;470(3):331-5 [10745091.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4026-35 [10921883.001]
  • [Cites] Acta Physiol Hung. 2000;87(1):5-24 [11032044.001]
  • [Cites] Kidney Int. 2000 Dec;58(6):2437-51 [11115077.001]
  • [Cites] Breast Cancer Res. 2000;2(1):32-44 [11250691.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1235-41 [12117783.001]
  • [Cites] Circulation. 2002 Aug 13;106(7):847-53 [12176959.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1305-17 [12379765.001]
  • [Cites] Mol Cancer Ther. 2002 Aug;1(10):777-83 [12492110.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):67-75 [12840060.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1817-26 [15111328.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Int J Cancer. 1989 Oct 15;44(4):707-13 [2793242.001]
  • [Cites] Peptides. 1992 Jul-Aug;13(4):783-6 [1437716.001]
  • [Cites] Biochem Biophys Res Commun. 1994 May 16;200(3):1449-54 [8185599.001]
  • [Cites] Prog Growth Factor Res. 1994;5(2):177-94 [7919223.001]
  • [Cites] Circulation. 1994 Nov;90(5):2414-24 [7525108.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):651-7 [7860748.001]
  • [Cites] Receptors Channels. 1994;2(4):271-80 [7719706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10663-7 [7479861.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11952-8 [9115258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 [9391118.001]
  • [Cites] Hum Gene Ther. 1998 Sep 20;9(14):1983-93 [9759926.001]
  • [Cites] Cancer Immunol Immunother. 1998 Nov;47(3):143-8 [9829839.001]
  • [Cites] J Neurochem. 1999 Jan;72(1):292-301 [9886081.001]
  • [Cites] Endocr Res. 1998 Aug-Nov;24(3-4):307-14 [9888502.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):343-8 [10207881.001]
  • [Cites] Cancer Lett. 1999 May 24;139(2):215-20 [10395181.001]
  • [Cites] Curr Opin Biotechnol. 1999 Oct;10(5):440-7 [10508634.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):271-9 [15637093.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2686-94 [15814650.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18237-44 [15746093.001]
  • [Cites] Med Sci Monit. 2005 Jun;11(6):RA194-205 [15917731.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S183-7 [16113095.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7660-5 [16140932.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):953-67 [16162972.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):552-60 [16434990.001]
  • [Cites] Expert Opin Drug Deliv. 2006 May;3(3):325-44 [16640494.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jul;3(7):388-98 [16826219.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):145-52 [17997512.001]
  • [Cites] Mol Cell Biochem. 2008 Aug;315(1-2):185-93 [18543083.001]
  • [Cites] J Mol Histol. 2008 Aug;39(4):351-8 [18438736.001]
  • [Cites] Cancer Lett. 2009 Jul 18;280(1):31-7 [19285791.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] IEEE Trans Nanobioscience. 2007 Dec;6(4):319-30 [18217625.001]
  • (PMID = 20026904.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017686; United States / NCRR NIH HHS / RR / RR017686-04; United States / NCRR NIH HHS / RR / P20 RR015563; United States / NCRR NIH HHS / RR / P20 RR017686-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FuGene; 0 / Lipids; 0 / Receptor, Angiotensin, Type 2
  •  go-up   go-down


38. Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K, Tamai S, Matsubara O: Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol; 2007 Jul;31(7):999-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.
  • We occasionally encountered clear cell adenofibromatous (CCAF) components coexisting in the ovarian clear cell adenocarcinoma (CCA).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenofibroma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Immunoenzyme Techniques. Japan / epidemiology. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592265.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


39. Bîrlă R, Losif C, Gîndea C, Hoară P, Constantinoiu S: [Treatment of the esophago-gastric junction adenocarcinoma]. Chirurgia (Bucur); 2008 Mar-Apr;103(2):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of the esophago-gastric junction adenocarcinoma].
  • [Transliterated title] Tratamentul adenocarcinomului de joncţiune esogastrică.
  • The aim of the work paper is to present the treatment methods of the esophago-gastric junction adenocarcinoma, (AC) based on our experience and literature data.
  • Surgical procedure selection at patients with resectable tumours should be based on the tendency of esophago-gastric junction adenocarcinomas to extend on longitudinal axis, at the submucosa level and the possibility of abdomino-mediastinal lymph nodes metastasis.
  • In located disease, tumoral resection R0 with abdominal and mediastinal lymph nodes dissection represents the optimal therapy, because it confers the best chance of cure.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457092.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 43
  •  go-up   go-down


40. Siewert JR, Ott K: Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol; 2007 Jan;17(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are squamous and adenocarcinomas of the esophagus the same disease?
  • Esophageal cancer can be divided in squamous-cell cancer (SCC) and adenocarcinoma (Barrett cancer: AEG I) by histopathology.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185196.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


41. Lagergren J, Jansson C, Viklund P: Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study. Eur J Cancer; 2006 Sep;42(14):2359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study.
  • The aim of this study was to test the hypothesis that chewing gum is associated with risk of oesophageal and cardia adenocarcinoma.
  • All patients were prospectively and uniformly documented and classified shortly after diagnosis.
  • In all, 189 and 262 patients with oesophageal and cardia adenocarcinoma, respectively, and 820 population-based control subjects were interviewed.
  • Regular users of chewing gum (P3 times/week for P6 months) were not at increased risk of oesophageal adenocarcinoma (OR 1.0, 95% CI 0.6-2.2), and no duration-response relation was observed (P = 0.38).
  • No association between regular gum chewing and cardia adenocarcinoma was found (OR 1.0, 95% CI 0.6-1.7), irrespective of duration of use (P = 0.56).
  • In conclusion, with regard to risk of oesophageal or cardia adenocarcinoma, gum chewing seems harmless.
  • [MeSH-major] Adenocarcinoma / etiology. Cardia. Chewing Gum / adverse effects. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890425.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chewing Gum
  •  go-up   go-down


42. Ben Temime L, Gherib BS, Daldoul S, Bel Hadj Salah R, Abdesselem Mel M, Zaouche A: [Adenocarcinoma at the site of ileo-anal anastomosis in Crohn's disease: report of a case]. Tunis Med; 2005 Jan;83(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma at the site of ileo-anal anastomosis in Crohn's disease: report of a case].
  • [Transliterated title] Adénocarcinome sur poche iléo-anale compli- quant une maladie de crohn. A propos d'un cas.
  • The pathological diagnosis carried of the specimen was Ulcerative colitis Then a proctectomy, followed by ileo-anal anastomosis, was performed in 1993.
  • After several episodes of pochitis and the appearance of intestinal lesions upstream the ileal pocket, the retained diagnosis was Crohn's colitis.
  • Eight years after the ileo-anal anastomosis, the patient developed an adenocarcinoma in the ileal pocket.
  • [MeSH-major] Adenocarcinoma / diagnosis. Anal Canal / surgery. Crohn Disease / surgery. Ileal Neoplasms / diagnosis. Ileum / surgery

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881724.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


43. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P: Pancreatic adenocarcinoma. Eur Radiol; 2007 Mar;17(3):638-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma.
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases.
  • By the time of diagnosis, at least 80% of tumors are unresectable.
  • Helical computed tomography (CT) is very effective in detecting and staging adenocarcinoma, with a sensitivity of up to 90% for detection and an accuracy of 80-90% for staging, but it has limitations in detecting small cancers.
  • MDCT has been found to be at least equivalent to contrast-enhanced magnetic resonance imaging (MRI) for detecting adenocarcinoma.
  • It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Endosonography. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):849-55 [10715057.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Abdom Imaging. 1997 Jul-Aug;22(4):429-33 [9157866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):204-7 [9013536.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):700-3 [16120921.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Pancreatology. 2001;1(6):610-24 [12120244.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):649-52 [9490946.001]
  • [Cites] Eur Radiol. 2005 Nov;15 Suppl 4:D96-9 [16479656.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):231-4 [11246351.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiology. 1997 Nov;205(2):513-8 [9356637.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Radiology. 1991 Aug;180(2):337-9 [1906189.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Br J Radiol. 2000 Nov;73(875):1165-9 [11144793.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Radiology. 1993 Mar;186(3):795-8 [8430190.001]
  • [Cites] Radiographics. 2005 Jul-Aug;25(4):949-65 [16009817.001]
  • [Cites] Radiology. 2001 Oct;221(1):107-16 [11568327.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Eur Radiol. 2005 Jun;15(6):1256-62 [15627187.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Invest Radiol. 1999 Sep;34(9):589-95 [10485075.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Br J Radiol. 1998 May;71(845):492-6 [9691893.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 5:M42-9 [14989611.001]
  • [Cites] Radiology. 2002 Dec;225(3):759-65 [12461258.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):119-23 [9207510.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] Eur Radiol. 1996;6(1):14-8 [8797944.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):677-84 [10701608.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12 ):2658-61 [16393216.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):2998-3008 [12439582.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Magn Reson Imaging. 2000 Aug;12 (2):261-8 [10931589.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] Rofo. 2004 Nov;176(11):1624-33 [15497081.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):743-9 [12439309.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 17021700.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 65
  •  go-up   go-down


44. Chalasani V, Macek P, O'Neill GF, Barret W: Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma. Can J Urol; 2010 Feb;17(1):5031-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma.
  • This article describes an unusual finding in a patient who presented with an adenocarcinoma of the prostate and right hydronephrosis.
  • Cystoscopy showed an exophytic superficial transitional cell carcinoma (TCC) of the bladder and a transrectal biopsy of the prostate confirmed adenocarcinoma Gleason score 4+3.
  • Staging investigations (CT pelvis and bone scan) were negative; androgen deprivation therapy was therefore initiated for the prostatic adenocarcinoma.
  • With a working diagnosis of upper tract TCC, right open nephroureterectomy was performed.
  • Final histology showed prostatic adenocarcinoma infiltrating the adventitia of the entire ureter up to the level of the renal pelvis.
  • A rare cause of ureteric stricture, contiguous spread of prostatic adenocarcinoma, should be considered in the differential diagnosis of patients presenting with upper tract obstruction and a known history of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Ureter / pathology. Ureteral Obstruction / etiology
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness


45. Autio A, Ujula T, Luoto P, Salomäki S, Jalkanen S, Roivainen A: PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG. Eur J Nucl Med Mol Imaging; 2010 Oct;37(10):1918-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG.
  • METHODS: Rats with both subcutaneous human pancreatic adenocarcinoma xenografts and turpentine oil-induced acute sterile inflammation were evaluated by dynamic positron emission tomography (PET) and by digital autoradiography of tissue cryosections.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Amine Oxidase (Copper-Containing) / metabolism. Cell Adhesion Molecules / metabolism. Cell Transformation, Neoplastic. Fluorodeoxyglucose F18. Heterocyclic Compounds, 1-Ring / chemistry. Peptides. Positron-Emission Tomography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1259-68 [16007423.001]
  • [Cites] J Nucl Med. 2001 May;42(5):808-17 [11337581.001]
  • [Cites] Mol Imaging Biol. 2010 Jun;12 (3):259-68 [19798536.001]
  • [Cites] J Nucl Med. 1995 Jul;36(7):1301-6 [7790960.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404 [15549297.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):616-23 [19093111.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):135-41 [18077525.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):17-27 [9653080.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):953-9; discussion 959-60 [14675704.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):3978-88 [9558106.001]
  • [Cites] Ann Nucl Med. 2006 Oct;20(8):527-33 [17134019.001]
  • [Cites] World J Gastroenterol. 2006 Jul 28;12(28):4466-72 [16874856.001]
  • [Cites] FASEB J. 2001 Feb;15(2):373-82 [11156953.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7875-83 [19789345.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] Cancer Invest. 1986;4(1):15-23 [3754176.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6937-43 [11359855.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):352-64 [18038133.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):983-92 [12097405.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):53-8 [11408922.001]
  • [Cites] J Comput Assist Tomogr. 1979 Jun;3(3):299-308 [438372.001]
  • [Cites] J Gastrointestin Liver Dis. 2008 Jun;17(2):173-8 [18568138.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):18-26 [17962625.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1326-35 [24578054.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1046-51 [9305704.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):389-97 [15372209.001]
  • [Cites] Nucl Med Biol. 2009 Aug;36(6):631-41 [19647169.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):317-22 [9639291.001]
  • [Cites] Ann Nucl Med. 2005 Oct;19(7):589-95 [16363624.001]
  • [Cites] Trends Immunol. 2001 Apr;22(4):211-6 [11274927.001]
  • (PMID = 20523988.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Gallium Radioisotopes; 0 / Heterocyclic Compounds, 1-Ring; 0 / Peptides; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1HTE449DGZ / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; EC 1.4.3.21 / AOC3 protein, human; EC 1.4.3.21 / Amine Oxidase (Copper-Containing)
  •  go-up   go-down


46. Zhou D, Hu C, Su X, Yang H: [Study on apoptosis of human lung adenocarcinoma cell line A549/DDP induced by ginsenoside Rh₂ in vitro]. Zhongguo Fei Ai Za Zhi; 2005 Aug 20;8(4):257-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on apoptosis of human lung adenocarcinoma cell line A549/DDP induced by ginsenoside Rh₂ in vitro].
  • The aim of this study is to investigate the apoptosis of human lung adenocarcinoma cell line A549/DDP induced by ginsenoside Rh₂ (G-Rh₂) and to explore its possible molecular mechanism.
  • (1) G-Rh₂ significantly inhibited the growth of A549/DDP cells in a dose-time-de-pendent manner. (2) After 24 hours' treatment with G-Rh₂, apoptosis index of trial group was significantly higher than that of control group (P < 0.001).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21108877.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer; 2009 Sep 15;115(18):4148-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
  • BACKGROUND: Advanced biliary tract adenocarcinoma (BTA) has been a rare but fatal cancer.
  • A Cox proportional hazards model indicated that metastatic disease (hazards ratio [HR], 1.521; P=.011), intrahepatic cholangiocellular carcinoma (HR, 1.368; P=.045), liver metastasis (HR, 1.845; P<.001), Eastern Cooperative Oncology Group performance status (HR, 1.707; P<.001), and alkaline phosphatase level (IU/L) (HR, 1.001; P<.001) were statistically significant independent predictors of poor prognosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Biliary Tract Neoplasms / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19536892.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Ueda J, Iwata T, Ono M, Takahashi M: Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol; 2006 Jan;34(1):6-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
  • We assessed whether a panel of seven antibodies is useful in the differentiation of adenocarcinoma cells (ACCs) from reactive mesothelial cells (RMCs) in effusion samples and to determine optimal specimen preparation conditions for immunocytochemical analysis of effusion samples.
  • Commercially available antibodies MOC-31, Ber-EP4, CA19-9, CEA, EMA, CA125, and HBME-1 were tested on RMCs from four samples of various etiology and 15 samples of adenocarcinoma from various primary sites.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Cytodiagnosis / methods. Histocytological Preparation Techniques. Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Biomarkers, Tumor / analysis. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Sensitivity and Specificity. Tissue Embedding / methods

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355377.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Jenkins JT, Charles A, Mitchell KG, Fullarton GM: Photodynamic therapy for Barretts' adenocarcinoma associated with an Angelchik device. Photodiagnosis Photodyn Ther; 2005 Sep;2(3):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for Barretts' adenocarcinoma associated with an Angelchik device.
  • We present a novel case of an elderly patient with a Barrett's adenocarcinoma in the presence of an Angelchik prosthesis.
  • We aim to draw attention to issues relating to metaplastic Barretts' oesphagus and its adenocarcinoma complications and highlight relevant issues in multimodal endoscopic management and palliation using photodynamic therapy in the presence of the device.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25048770.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Ho CH, Lin WC, Pu YS, Yu HJ, Huang CY: Primary mucinous adenocarcinoma of renal pelvis with carcinoembryonic antigen production. Urology; 2008 May;71(5):984.e7-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of renal pelvis with carcinoembryonic antigen production.
  • We report a case of primary mucinous adenocarcinoma of the renal pelvis associated with carcinoembryonic antigen (CEA) production.
  • Radical nephrectomy was performed, and the histopathologic examination revealed a mucinous adenocarcinoma that was strongly positive for CEA.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Carcinoembryonic Antigen / biosynthesis. Kidney Neoplasms / metabolism. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2009 Aug;74(2):475 [19646634.001]
  • (PMID = 18291507.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


51. Wang T, Kang CS, Wang BM, Zhang QY: [The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]. Zhonghua Nei Ke Za Zhi; 2008 Feb;47(2):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell].
  • OBJECTIVE: To observe the cyclooxygenase-2 (COX-2) expression and the cell proliferation and apoptosis of gastric adenocarcinoma cells after transiently transfecting gastric cancer cells using specific COX-2 small interfering RNA (siRN) and discuss the role of COX-2 in gastric tumorigenesis and the effect of RNA interference (RNAi) as anti-cancer gene therapy.
  • Gastric adenocarcinoma cells SGC7901 were cultured at 37 degrees C in an atmosphere containing 5% CO2.
  • CONCLUSIONS: The experimental results suggest that effectively inhibiting the expression of COX-2 can suppress the proliferation of gastric adenocarcinoma cell and promote the process of cancer cell apoptosis, so RNAi is a powerful tool of gene therapeutic method.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Humans. Immunohistochemistry. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683800.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


52. Duan L, Huang Y, Li G, Liu X, Zhang Y: [The role and significance of serum SYK and VEGF-C in metastasis of the lymph nodes of pulmonary adenocarcinoma.]. Zhongguo Fei Ai Za Zhi; 2008 Dec 20;11(6):802-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role and significance of serum SYK and VEGF-C in metastasis of the lymph nodes of pulmonary adenocarcinoma.].
  • BACKGROUND: Lung cancer has become one of the most dangerous malignant tumor in the world nowadays, whose pathogenesis is complex involving multi-genes and multi-elements.
  • In this study, we try to explore the values of serum SYK and vascular endothelial growth factor-C (VEGF-C) in lymph node metastasis of lung adenocarcinoma.
  • METHODS: Serum SYK and VEGF were examined in 160 lung adenocarcinoma patients with various metastasis lesions and 40 healthy volunteers by ELISA.
  • RESULTS: The serum SYK level of the lung adenocarcinoma patients were remarkably lower than those of normal persons (P <0.05); The SYK level decreased while the lymph nodes area increased along with their metastasis (P <0.05), and the serum VEGF-C level were remarkably higher than those of healthy objects (P <0.05).
  • CONCLUSIONS: The serum level of SYK and VEGF-C are closely related to the lymph nodes metastasis of lung adenocarcinoma.
  • Combination detection of SYK and VEGF-C might be helpful for the predict of lymph nodes metastasis of lung adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20797333.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Fichna J, do-Rego JC, Mirowski M, Costentin J, Janecka A: Binding of endomorphin-2 to mu-opioid receptors in experimental mouse mammary adenocarcinoma. J Pept Res; 2005 Apr;65(4):459-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Binding of endomorphin-2 to mu-opioid receptors in experimental mouse mammary adenocarcinoma.
  • In the present study, [125I]endomorphin-2 has been used to characterize mu-opioid-binding sites on transplantable mouse mammary adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Mammary Neoplasms, Experimental / metabolism. Oligopeptides / metabolism. Receptors, Opioid, mu / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813894.001).
  • [ISSN] 1397-002X
  • [Journal-full-title] The journal of peptide research : official journal of the American Peptide Society
  • [ISO-abbreviation] J. Pept. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Oligopeptides; 0 / Receptors, Opioid, mu; 0 / endomorphin 2
  •  go-up   go-down


54. Eom BW, Jung SY, Yoon H, Kook MC, Ryu KW, Lee JH, Kim YW: Gastric choriocarcinoma admixed with an alpha-fetoprotein-producing adenocarcinoma and separated adenocarcinoma. World J Gastroenterol; 2009 Oct 28;15(40):5106-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric choriocarcinoma admixed with an alpha-fetoprotein-producing adenocarcinoma and separated adenocarcinoma.
  • We report a case of gastric choriocarcinoma admixed with an alpha-fetoprotein (AFP)-producing adenocarcinoma.
  • Histopathological evaluation confirmed double primary gastric cancer: gastric choriocarcinoma admixed with an AFP-producing adenocarcinoma and separated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Choriocarcinoma / diagnosis. Stomach Neoplasms / diagnosis. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):654-61 [7508672.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1075-9 [7487411.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):1045-6 [8633553.001]
  • [Cites] Cancer. 1953 Mar;6(2):319-26 [13032923.001]
  • [Cites] Am J Surg. 1960 Aug;100:224-33 [14436952.001]
  • [Cites] Gastric Cancer. 2005;8(3):178-85 [16086121.001]
  • [Cites] Gastric Cancer. 2002;5(2):112-7 [12111588.001]
  • [Cites] Diagn Mol Pathol. 2001 Sep;10(3):161-5 [11552718.001]
  • [Cites] Surg Today. 2007;37(11):995-9 [17952534.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Kurume Med J. 2003;50(1-2):63-6 [12971266.001]
  • [Cites] Am J Gastroenterol. 1988 Oct;83(10):1172-5 [3048084.001]
  • [Cites] Ann Thorac Surg. 1992 Jan;53(1):151-2 [1370196.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):321-5 [1371637.001]
  • [Cites] J Urol. 1994 Sep;152(3):958-60 [7519684.001]
  • (PMID = 19860007.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2768893
  •  go-up   go-down


55. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH: Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg; 2005 Nov;130(5):1378
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
  • METHODS: We collected tissues from 72 patients with lung adenocarcinomas.
  • Pathologic stage (P = .023), unmethylation of DAPK from normal tissue (P = .043), and hypermethylation of RARbetaP2 from normal tissue (P = .030) were risk factors for disease-free survival.
  • CONCLUSIONS: DNA methylation status of CpG islands seems to be a useful predictor of long-term outcome for adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / metabolism. CpG Islands. DNA Methylation. Lung Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Promoter Regions, Genetic. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256792.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Stevens JJ, Graham-Evans B, Walker AM, Armstead B, Tchounwou PB: Cytotoxic Effect of Arsenic Trioxide in Adenocarcinoma Colorectal Cancer (HT-29) Cells. Met Ions Biol Med; 2008 Jan 1;10:458-462
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic Effect of Arsenic Trioxide in Adenocarcinoma Colorectal Cancer (HT-29) Cells.
  • Hence, the aim of the present study was to investigate the cytotoxic effects of arsenic trioxide (As(2)O(3)) on adenocarcinoma colorectal cancer (HT-29) cells using the MTT [3-(4,5 dimethylthiazoyl-2-yl)-2,5- diphenyltetrazolium bromide] assay for cell viability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21603592.001).
  • [ISSN] 1257-2535
  • [Journal-full-title] Metal ions in biology and medicine : proceedings of the ... International Symposium on Metal Ions in Biology and Medicine held ... = Les ions metalliques en biologie et en medecine : ... Symposium international sur les ions metalliques ...
  • [ISO-abbreviation] Met Ions Biol Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR013459; United States / NIGMS NIH HHS / GM / R25 GM067122; United States / NCRR NIH HHS / RR / RR013459-115530
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] France
  •  go-up   go-down


57. Negi SS, Agarwal A, Chaudhary A: Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. Invest New Drugs; 2006 May;24(3):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
  • METHODS: This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma.
  • RESULTS: Both the groups were well matched with regards to demographic, disease related and treatment variables.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Flutamide / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1982 Oct;69(10):595-7 [7127040.001]
  • [Cites] BMJ. 1998 Jun 27;316(7149):1935-8 [9641928.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Jan 8;286(6359):93-5 [6401508.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):789-92 [2529892.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):321-4 [3536580.001]
  • [Cites] Br J Surg. 1990 Jul;77(7):725-30 [2200555.001]
  • [Cites] Eur J Surg Oncol. 1986 Mar;12(1):69-70 [3956756.001]
  • [Cites] Cancer. 1984 Feb 1;53(3 Suppl):630-43 [6692266.001]
  • [Cites] Eur J Surg Oncol. 1988 Jun;14(3):199-202 [3371470.001]
  • [Cites] Invest New Drugs. 1997;15(4):361-4 [9547680.001]
  • [Cites] Horm Metab Res. 1997 Mar;29(3):115-8 [9137981.001]
  • [Cites] Oncology. 1998 Dec;55 Suppl 1:17-22 [9852398.001]
  • [Cites] BMJ. 1999 Jan 30;318(7179):327-8 [10075464.001]
  • [Cites] Gastroenterology. 1986 Oct;91(4):1002-6 [3017803.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):384-6 [8472160.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):716-9 [12232752.001]
  • [Cites] Int J Pancreatol. 1989 May;4(4):363-9 [2659684.001]
  • [Cites] Cancer Treat Rep. 1987 Jul-Aug;71(7-8):749-50 [3038316.001]
  • [Cites] Drugs Aging. 2000 Sep;17(3):161-3 [11043816.001]
  • [Cites] Cancer. 1986 May 15;57(10):1992-5 [3955505.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):503-6 [1520587.001]
  • [Cites] Eur J Surg Oncol. 1989 Jun;15(3):236-41 [2567682.001]
  • [Cites] Hepatogastroenterology. 1991 Apr;38(2):165-9 [1855775.001]
  • [Cites] Pancreas. 1987;2(6):684-7 [3438305.001]
  • (PMID = 16133790.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 76W6J0943E / Flutamide
  •  go-up   go-down


58. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer; 2007 Sep;57(3):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
  • Data from large phase II trials of non-small cell lung cancer (NSCLC) suggested that the histologic subtype of adenocarcinoma may be a prognostic factor for patients treated with gefitinib.
  • To evaluate the efficacy of gefitinib in palliative therapy for advanced patients with adenocarcinoma and brain metastases, we conducted a phase II study.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed adenocarcinoma and brain metastases confirmed with radiological studies.
  • RESULTS: The overall objective response rate was 32% with a disease control rate of 77%.
  • CONCLUSIONS: Our data suggest that gefitinib has promising activity in palliative therapy for patients with advanced lung adenocarcinoma and brain metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Lung Neoplasms / drug therapy. Palliative Care. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Quality of Life. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434236.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


59. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC: Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol; 2010 Apr;17(4):981-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
  • BACKGROUND: Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant chemoradiation (CRT) may decrease survival compared with surgery alone.
  • Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adenocarcinoma compared with surgery alone.
  • MATERIALS AND METHODS: Patients with pancreatic adenocarcinoma at Johns Hopkins Hospital (n = 794, 1993-2005) and Mayo Clinic (n = 478, 1985-2005) following resection who were observed (n = 509) or received adjuvant 5-FU based CRT (median dose 50.4 Gy; n = 583) were included.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Pancreaticoduodenectomy. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1565-6 [11716876.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):694; author reply 694-6 [12409677.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):74-85 [12496533.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1249-51 [15028829.001]
  • [Cites] Acad Emerg Med. 2004 Sep;11(9):953-61 [15347546.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):358-65 [3632096.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):483-9 [8390422.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6 [15752874.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):403-16 [16549335.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):332-3; author reply 333 [16858208.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1019-26 [18319412.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3511-6 [18640932.001]
  • [CommentIn] Ann Surg Oncol. 2010 Apr;17(4):950-2 [20012500.001]
  • (PMID = 20087786.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2840672
  •  go-up   go-down


60. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, Ouellette MM: Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology; 2007 Oct;51(4):539-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
  • Pancreatic ductal adenocarcinomas show limited responsiveness to taxanes, but little is known of the underlying mechanisms.
  • The aim of this study was to examine TUBB3 expression in pancreatic cancer cell lines, invasive pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • Immunohistochemistry was employed to assess TUBB3 in pancreatic cancer specimens, including 75 invasive adenocarcinomas and 41 PanIN precursor lesions.
  • In contrast, the vast majority (78-93%) of pancreatic ductal adenocarcinomas demonstrated either diffuse or focal TUBB3 expression.
  • CONCLUSIONS: TUBB3 is expressed in most pancreatic ductal adenocarcinomas, possibly accounting for the suboptimal response of these tumours to microtubule-stabilizing agents.
  • Up-regulation of TUBB3 in PanIN lesions suggests that microtubule dysfunction is an early feature of this disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma in Situ / metabolism. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Pancreatic Neoplasms / metabolism. Tubulin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714470.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / TUBB3 protein, human; 0 / Tubulin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


61. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV: Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg; 2010 Jul;97(7):1020-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma.
  • BACKGROUND: Obesity is associated with oesophageal adenocarcinoma, but mechanisms linking fat and carcinogenesis remain poorly understood.
  • METHODS: Seventy-five patients with oesophageal adenocarcinoma underwent anthropometric and radiological assessment of obesity.
  • The human oesophageal adenocarcinoma cell line OE33 was used as the calibrator sample.
  • CONCLUSION: Obesity is associated with upregulated ObR and AdipR2 expression in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Esophageal Neoplasms. Esophagogastric Junction. Obesity, Abdominal / complications. Receptors, Adiponectin / metabolism. Receptors, Leptin / metabolism
  • [MeSH-minor] Adipokines / metabolism. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Female. Humans. Intra-Abdominal Fat. Male. Middle Aged. Neoplasm Staging. Up-Regulation

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20632267.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOR1 protein, human; 0 / ADIPOR2 protein, human; 0 / Adipokines; 0 / Receptors, Adiponectin; 0 / Receptors, Leptin
  •  go-up   go-down


62. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of pancreatic adenocarcinoma by imaging studies.
  • Imaging studies play a crucial role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with pancreatic adenocarcinoma.
  • The sensitivity of CT for diagnosis of pancreatic adenocarcinoma (89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.
  • Magnetic resonance imaging has not been shown to perform better than CT for the diagnosis and staging of pancreatic adenocarcinoma, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.
  • Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for diagnosis and staging of patients with pancreatic adenocarcinoma is limited.
  • Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with pancreatic adenocarcinoma, but its utility has not been established.
  • Endoscopic ultrasound is generally considered superior to CT for the diagnosis and local staging of pancreatic cancer, but is limited by availability and inability to assess for distant metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreas / radiography. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948228.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


63. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • METHODS: A total of 104 gastric adenocarcinomas from 98 patients (88 infiltrative and 16 intraepithelial tumors) were assessed immunohistochemically for expression of iNOS and occurrence of nitrotyrosine (NTYR)-containing proteins and 8-hydroxy-2'-deoxyguanosine (8-OH-dG)-containing DNA, as markers of NO production and damages to protein and DNA.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


64. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res; 2005 Mar 1;65(5):1642-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
  • Only one adenocarcinoma cell line (NCI-H1781) had a mutation.
  • HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003).
  • In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%).
  • The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Mutation / genetics


65. Wakabayashi N, Tsujino M, Tajiri M, Taki M, Koshino A, Ikeda H, Fukushima N, Tsujiuchi T: No Mutations of Lysophosphatidic Acid Receptor Genes in Lung Adenocarcinomas Induced by N-Nitrosobis(2-hydroxypropyl)amine in Rats. J Toxicol Pathol; 2010 Mar;23(1):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No Mutations of Lysophosphatidic Acid Receptor Genes in Lung Adenocarcinomas Induced by N-Nitrosobis(2-hydroxypropyl)amine in Rats.
  • Recently, frequent mutations of the LPA receptor-1 (LPA1) gene were detected in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine (BHP).
  • In this study, to evaluate the involvement of other LPA receptor gene alterations during lung carcinogenesis, we investigated mutations of the LPA2, LPA3, LPA4 and LPA5 genes in lung adenocarcinomas induced by BHP in rats.
  • Fifteen male Wistar rats, 6 weeks of age, were given 2000 ppm BHP in their drinking water for 12 weeks and then maintained without further treatment until sacrifice at 25 weeks, and 15 adenocarcinomas were obtained.
  • No mutations of LPA2, LPA3, LPA4 and LPA5 were detected in the 15 adenocarcinomas.
  • These results suggest that alterations due to LPA2, LPA3, LPA4 and LPA5 gene mutations might not be involved in the development of lung adenocarcinomas induced by BHP in rats.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22272013.001).
  • [ISSN] 1881-915X
  • [Journal-full-title] Journal of toxicologic pathology
  • [ISO-abbreviation] J Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3234649
  • [Keywords] NOTNLM ; N-nitrosobis(2-hydroxypropyl)amine / lung adenocarcinoma / lysophosphatidic acid receptor / mutation / rat
  •  go-up   go-down


66. Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H, Katano M: Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes. Anticancer Res; 2010 Dec;30(12):4999-5010
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes.
  • To enable the development of taxane-based chemotherapy for pancreatic ductal adenocarcinoma (PDAC), this study investigated the molecular mechanisms by which γ-secretase (GS) complexes regulate taxane sensitivity.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187481.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Presenilin-1; 0 / Presenilin-2; 0 / Receptors, Notch; 0 / Taxoids; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


67. Schmidt CM, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q, Howard TJ, Madura JA, Nakeeb A, Pitt HA, Cameron JL, Yeo CJ, Lillemoe KD: Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery; 2007 Oct;142(4):572-8; discussion 578-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma.
  • In patients undergoing pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC), conversion to total pancreatectomy (TP) may be necessary to achieve R0 resection.
  • CONCLUSIONS: Conversion of PD to TP to achieve an R0 resection in patients with pancreatic adenocarcinoma is associated with a survival benefit.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Pancreatectomy / mortality. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950350.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ju W, Park HM, Lee SN, Sung SH, Kim SC: Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Oct;32(5):454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma.
  • AIM: To assess the incidence and clinicopathological significance of microsatellite instability (MSI) and the protein expression of hMLH1 and hMSH2 in sporadic endometrioid endometrial adenocarcinoma (SEEA).
  • METHODS: A total of 50 patients with pure endometrioid sporadic endometrial adenocarcinoma were enrolled in the study.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Female. Humans. Immunohistochemistry. Microsatellite Repeats / genetics. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984511.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


69. Pavlichenko OV, Shishkin AN, Stepanova EV, Dubovaya TK, Krasil'nikov MA: Development of differential sensitivity of CaOv ovarian adenocarcinoma cells to antitumor agents under conditions of hypoxia. Bull Exp Biol Med; 2006 Oct;142(4):474-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of differential sensitivity of CaOv ovarian adenocarcinoma cells to antitumor agents under conditions of hypoxia.
  • Hypoxia-resistant CaOv/H substrain with high level of VEGF-A secretion was obtained by long-term culturing of CaOv ovarian adenocarcinoma cells with CoCl2 (hypoxia inductor).
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Count. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Cobalt / pharmacology. Female. Humans. Ovarian Neoplasms / pathology. Vascular Endothelial Growth Factor A / pharmacology

  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • Hazardous Substances Data Bank. COBALTOUS CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415441.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng; rus
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 3G0H8C9362 / Cobalt; EVS87XF13W / cobaltous chloride
  •  go-up   go-down


70. Hara S, Kijima H, Okada K, Igarashi Y: Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis. Biomed Res; 2010 Apr;31(2):89-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis.
  • We analyzed the clinicopathologic findings of IMPV and compared them with those of a conventional adenocarcinoma in the gallbladder to clarify the highly aggressive potential of IMPV of gallbladder carcinoma.
  • IMPV is a useful predictor of regional lymph node metastasis in gallbladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma / pathology. Gallbladder Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Multivariate Analysis. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460736.001).
  • [ISSN] 1880-313X
  • [Journal-full-title] Biomedical research (Tokyo, Japan)
  • [ISO-abbreviation] Biomed. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, Pyronnet S, Castronovo V, Schilling MK, Bikfalvi A, Hagedorn M: Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology; 2010 Apr;138(4):1595-606, 1606.e1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells.
  • BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers.
  • METHODS: Human pancreatic adenocarcinoma cells were grafted onto the chick chorioallantoic membrane (CAM).
  • [MeSH-major] Adenocarcinoma / pathology. Endothelial Cells / physiology. Nerve Growth Factors / physiology. Pancreatic Neoplasms / pathology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Apoptosis. CA-19-9 Antigen / blood. Cell Line, Tumor. Chick Embryo. Disease Progression. Gene Expression Profiling. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20080097.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE14509
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1
  •  go-up   go-down


72. Eisenberger CF, Stoecklein NH, Jazra S, Hosch SB, Peiper M, Scheunemann P, Am Esch JS, Knoefel WT: The detection of oesophageal adenocarcinoma by serum microsatellite analysis. Eur J Surg Oncol; 2006 Nov;32(9):954-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of oesophageal adenocarcinoma by serum microsatellite analysis.
  • MATERIAL AND METHODS: Matched normal-, tumour- and serum-samples were obtained from 32 patients with adenocarcinoma of the oesophagus.
  • RESULTS: Twenty-seven of the 32 patients (84.4%) with malignant tumours were found to have one or more microsatellite DNA alterations in their primary tumour.
  • Up to now the follow-up is still too short to draw further conclusions on the prognostic impact of this finding.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / genetics. Microsatellite Repeats / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Case-Control Studies. Chi-Square Distribution. DNA, Neoplasm / genetics. Female. Genes, APC. Genes, p16. Genes, p53. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584865.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


73. Ishihama H, Chida M, Araki O, Karube Y, Seki N, Tamura M, Umezu H, Honma K, Masawa N, Miyoshi S: Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol; 2009 Jan;39(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
  • BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas.
  • METHODS: We investigated the 5-FU-related gene expression levels of thymidylate synthase (TS), DPD, thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) in resected tumor specimens from 51 patients with adenocarcinomas and 47 with squamous cell carcinomas using quantitative reverse transcription-PCR, and compared those levels between the two histological types.
  • RESULTS: The relative gene expression values of TS, TP and OPRT were significantly lower in adenocarcinomas compared with squamous cell carcinomas, 1.60 +/- 0.86 versus 4.33 +/- 3.40 (P < 0.001), 0.84 +/- 0.52 versus 2.27 +/- 1.16 (P = 0.006) and 9.59 +/- 6.30 versus 16.94 +/- 12.04 (P < 0.001), respectively.
  • The relative gene expression value of DPD was significantly greater in adenocarcinomas than those in squamous cell carcinomas, 2.33 +/- 1.22 versus 1.50 +/- 1.20 (P = 0.01).
  • Lower expressions of TS and TP were observed more in adenocarcinomas (89.8%) than in squamous cell carcinomas (48.9%) (P < 0.001).
  • CONCLUSION: These data may explain that post-operative adjuvant chemotherapy with UFT was associated with improved survival in stage I patients with adenocarcinoma, but less with squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / genetics. Fluorouracil / therapeutic use. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics
  • [MeSH-minor] Aged. Dihydrouracil Dehydrogenase (NADP) / genetics. Female. Humans. Male. Neoplasm Staging. Orotate Phosphoribosyltransferase / genetics. Prognosis. Thymidine Phosphorylase / genetics. Thymidylate Synthase / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015148.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Comba A, Maestri DM, Berra MA, Garcia CP, Das UN, Eynard AR, Pasqualini ME: Effect of ω-3 and ω-9 fatty acid rich oils on lipoxygenases and cyclooxygenases enzymes and on the growth of a mammary adenocarcinoma model. Lipids Health Dis; 2010;9:112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of ω-3 and ω-9 fatty acid rich oils on lipoxygenases and cyclooxygenases enzymes and on the growth of a mammary adenocarcinoma model.
  • We studied the effect of two diets enriched in 6% Walnut and Peanut oils that are rich in ω-3 and ω9 PUFAs respectively on a murine mammary gland adenocarcinoma as compared with the control (C) that received commercial diet.
  • [MeSH-major] Adenocarcinoma / diet therapy. Arachidonate Lipoxygenases / metabolism. Fatty Acids, Omega-3 / administration & dosage. Fatty Acids, Unsaturated / administration & dosage. Mammary Neoplasms, Experimental / diet therapy. Prostaglandin-Endoperoxide Synthases / metabolism
  • [MeSH-minor] Animals. Apoptosis. Arachis / chemistry. Female. Juglans / chemistry. Male. Mice. Mice, Inbred BALB C. Mitosis. Neoplasm Transplantation. Nuts / chemistry. Plant Oils / administration & dosage. Plant Oils / chemistry. Random Allocation. Tumor Burden

  • Hazardous Substances Data Bank. Peanut oil .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2000 Dec;63(6):377-83 [11133175.001]
  • [Cites] FASEB J. 2000 Apr;14(5):661-8 [10744623.001]
  • [Cites] Biomed Pharmacother. 2002 Jul;56(5):215-22 [12199620.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Jan;68(1):9-16 [12538085.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6370-7 [14559826.001]
  • [Cites] Endocrinology. 1987 May;120(5):2029-36 [3106013.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Dec 16;149(2):735-43 [3122740.001]
  • [Cites] Immunology. 1988 May;64(1):81-5 [3133309.001]
  • [Cites] J Hepatol. 1988 Dec;7(3):352-61 [3148653.001]
  • [Cites] J Biol Chem. 1989 Oct 25;264(30):18128-36 [2808369.001]
  • [Cites] Eur J Biochem. 1991 Jan 30;195(2):465-75 [1847684.001]
  • [Cites] Cancer Lett. 1991 Mar;56(3):235-43 [1850658.001]
  • [Cites] J Leukoc Biol. 1993 Feb;53(2):151-6 [7680370.001]
  • [Cites] J Leukoc Biol. 1993 May;53(5):550-8 [8388910.001]
  • [Cites] Int J Immunopharmacol. 1994 May-Jun;16(5-6):397-9 [7927985.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1994 Jun;50(6):331-4 [7938085.001]
  • [Cites] Mol Cell Biochem. 1995 Feb 23;143(2):89-98 [7596352.001]
  • [Cites] J Immunol Methods. 1995 Jul 17;184(1):39-51 [7622868.001]
  • [Cites] Cancer Lett. 1995 Aug 1;94(2):147-55 [7634242.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jan 14;242(2):413-8 [9446809.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):2934S-2945S [16382507.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1225-41 [16288226.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18601-9 [16638750.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Dec;7(6):467-82 [17168664.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4328-36 [17483346.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2007 Jul;77(1):21-8 [17618100.001]
  • [Cites] Arch Biochem Biophys. 2007 Dec 1;468(1):114-20 [17963719.001]
  • [Cites] Lipids Health Dis. 2008;7:9 [18348729.001]
  • [Cites] Arch Pharm Res. 2008 Apr;31(4):503-10 [18449509.001]
  • [Cites] Biochem Pharmacol. 2009 Jan 1;77(1):1-10 [18761324.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):924-31 [19035453.001]
  • [Cites] Int Immunopharmacol. 2009 Jun;9(6):701-15 [19239926.001]
  • [Cites] Neoplasia. 2009 Jul;11(7):692-9 [19568414.001]
  • [Cites] Oncogene. 2010 Feb 11;29(6):781-8 [19946329.001]
  • [Cites] Nutr Cancer. 2010;62(3):284-96 [20358465.001]
  • [Cites] Pancreatology. 2009;9(6):724-8 [20016244.001]
  • [Cites] Sci Total Environ. 2010 Sep 1;408(19):4056-61 [20541790.001]
  • [Cites] Nat Med. 2010 Aug;16(8):861-2 [20689550.001]
  • [Cites] Nat Med. 2010 Aug;16(8):863-4 [20689551.001]
  • [Cites] Nutrition. 2011 Jan;27(1):21-5 [20570489.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1999 Sep;61(3):157-63 [10582655.001]
  • [Cites] Biochim Biophys Acta. 2000 Jan 3;1483(1):174-84 [10601706.001]
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • (PMID = 20932327.001).
  • [ISSN] 1476-511X
  • [Journal-full-title] Lipids in health and disease
  • [ISO-abbreviation] Lipids Health Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Unsaturated; 0 / Plant Oils; 8002-03-7 / arachis oil; EC 1.13.11.- / Arachidonate Lipoxygenases; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Other-IDs] NLM/ PMC2959203
  •  go-up   go-down


75. Sharma S, Gupta R, Sharma R, Kotru M: Mucin-secreting gastric adenocarcinoma with Rhabdoid areas. Saudi J Gastroenterol; 2010 Jan-Mar;16(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-secreting gastric adenocarcinoma with Rhabdoid areas.
  • In this report, we describe the case of a 40-year-old patient with gastric adenocarcinoma composed of histologically well-differentiated glandular areas and focal rhabdoid zones.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary. Rhabdoid Tumor / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1999;195(12):841-6 [10631720.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):231-6 [12232582.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):357-63 [12478486.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):271-3 [15043320.001]
  • [Cites] Ultrastruct Pathol. 2004 May-Jun;28(3):165-70 [15471430.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(6):509-14 [2445098.001]
  • [Cites] Pathol Int. 1999 Feb;49(2):160-3 [10355971.001]
  • [Cites] Genomics. 1994 Feb;19(3):433-40 [8188285.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):233-48 [8545590.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):327-37 [8780932.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1322-6 [8918447.001]
  • [Cites] Histopathology. 1996 Dec;29(6):507-16 [8971557.001]
  • [Cites] Neuroradiology. 1997 Oct;39(10):719-23 [9351109.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):645-8 [1700599.001]
  • (PMID = 20065575.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3023103
  •  go-up   go-down


76. Balachandran A, Darden DL, Tamm EP, Faria SC, Evans DB, Charnsangavej C: Arterial variants in pancreatic adenocarcinoma. Abdom Imaging; 2008 Mar-Apr;33(2):214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial variants in pancreatic adenocarcinoma.
  • Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Celiac Artery / abnormalities. Mesenteric Arteries / abnormalities. Pancreas / blood supply. Pancreatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17435979.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 22
  •  go-up   go-down


77. Wucherer KL, Wilke V: Thyroid cancer in dogs: an update based on 638 cases (1995-2005). J Am Anim Hosp Assoc; 2010 Jul-Aug;46(4):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No sex predisposition was evident, but dogs between 10 and 15 years of age had a significantly increased chance of developing thyroid disease.
  • Carcinomas and adenocarcinomas represented 90% of thyroid cancers, while adenomas represented 9.3%.
  • Thyroid carcinoma and adenocarcinoma continue to be uncommon in our canine population.
  • A new finding is that Siberian huskies are also overrepresented.
  • Carcinomas represent a much higher proportion of thyroid cancers than previously reported, and adenomas are likely incidental findings on necropsy.
  • [MeSH-major] Adenocarcinoma / veterinary. Carcinoma / veterinary. Dog Diseases / epidemiology. Thyroid Neoplasms / veterinary
  • [MeSH-minor] Age Factors. Animals. Breeding. Dogs. Female. Genetic Predisposition to Disease. Incidence. Male. Odds Ratio. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610697.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Wu H, Deng J, Yu S, Wang X, Chen Y: The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms. J Huazhong Univ Sci Technolog Med Sci; 2010 Feb;30(1):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms.
  • In order to investigate the inhibitory effects of Endostar (rh-endostatin, YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the interaction mechanisms of combined therapy, the transplantation tumor models of A549 lung adenocarcinoma were established.
  • It was concluded that Endostar obviously enhanced the curative effectiveness of radiotherapy on lung adenocarcinoma A549 in mice.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / therapeutic use. Endostatins / therapeutic use. Lung Neoplasms / therapy. Radiotherapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 May 29;61(5):732-7 [7768649.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):976-83 [15985216.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84 [17644065.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4301-9 [11908684.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5565-70 [11034104.001]
  • [Cites] Evid Based Complement Alternat Med. 2005 Sep;2(3):387-93 [16136218.001]
  • [Cites] Int J Mol Med. 2005 Jul;16(1):159-64 [15942693.001]
  • [Cites] Circ Res. 1997 Jun;80(6):845-52 [9168787.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):287-91 [9685160.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):973-85 [11240238.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Nov;30(11):1169-74 [9839443.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2641-58 [3282647.001]
  • [Cites] Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90 [21108883.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12 (9):2706-15 [16675562.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5670-4 [17908955.001]
  • [Cites] Oncogene. 2001 Mar 15;20(11):1388-97 [11313882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):759-66 [15465192.001]
  • (PMID = 20155466.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / endostar protein; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


79. Reuss R, Aberle S, Klingel K, Sauter M, Greschniok A, Franke FE, Padberg W, Blin N: The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas. Int J Oncol; 2006 Sep;29(3):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas.
  • A minor expression was noted in a single sample of acinar cell carcinoma and adenocarcinomas did not show any expression.
  • By RT-PCR, no specific expression in both tested adenocarcinomas was observed.
  • In summary, these results show that, contrary to notable expression of carboxyl ester lipase in acinar cells of normal pancreatic tissue, this lipase is not significantly active in pancreatic adenocarcinomas and thus not an apt genetic marker for diagnostic or therapeutic approaches.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / genetics. Carcinoma, Acinar Cell / enzymology. Carcinoma, Acinar Cell / genetics. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / genetics. Humans. In Situ Hybridization. Liver Neoplasms / enzymology. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Pancreatitis / enzymology. Pancreatitis / genetics. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865281.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA Probes; 0 / RNA, Messenger; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


80. Wu CC, Shyu RY, Chou JM, Jao SW, Chao PC, Kang JC, Wu ST, Huang SL, Jiang SY: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer; 2006 Mar;42(4):557-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma.
  • Its expression is frequently down-regulated through DNA hypermethylation in several types of malignant tissues.
  • This study investigated the clinical significance of RARRES1 protein and its association with RARRES3 protein expression in 161 (26 adenoma, 13 distal normal mucosa and 122 primary colorectal adenocarcinoma) paraffin-embedded colorectal tissues by immunohistochemistry.
  • RARRES1 protein was detected at the highest levels in terminally differentiated cells of normal mucosal tissues and all 26 adenoma tissues.
  • Among 122 colorectal adenocarcinomas, the poorly differentiated adenocarcinomas and Dukes' stage D tumours showed a significant decrease in RARRES1 expression (P < 0.001 and P < 0.01, respectively).
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging / methods. Receptors, Retinoic Acid / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426842.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RARRES3 protein, human; 0 / Receptors, Retinoic Acid
  •  go-up   go-down


81. Eandi JA, Asuncion A, Vandewalker KN, Javidan J: Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma. Int J Urol; 2007 Sep;14(9):862-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the urinary bladder with pseudoepitheliomatous hyperplasia and colocalization with adenocarcinoma.
  • This case also represents the first granular cell tumor to demonstrate colocalization with adenocarcinoma of the bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Granular Cell Tumor / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760758.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


82. Ra YJ, Bae MJ, Kim YS, Choi KU: Difficulties in diagnosis and treatment of thymic adenocarcinoma producing beta-human chorionic gonadotropin in anterior mediastinum. Interact Cardiovasc Thorac Surg; 2010 Jul;11(1):114-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulties in diagnosis and treatment of thymic adenocarcinoma producing beta-human chorionic gonadotropin in anterior mediastinum.
  • On the pathological examination after the second operation, the tumor was diagnosed as thymic adenocarcinoma producing beta-hCG, and the tumor had originated from the thymus.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Thoracic Surgical Procedures. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421278.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


83. Lee SH, Ahn BK, Chang HK, Baek SU: Adenocarcinoma in ileal pouch after proctocolectomy for familial adenomatous polyposis: report of a case. J Korean Med Sci; 2009 Oct;24(5):985-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in ileal pouch after proctocolectomy for familial adenomatous polyposis: report of a case.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis is one of the surgical treatments of choice for patients with familial adenomatous polyposis.
  • Although the risk of cancer developing in an ileal pouch is not yet clear, a few cases of adenocarcinoma arising in an ileal pouch have been reported.
  • We report a case of adenocarcinoma in ileal pouch after proctocolectomy with ileal pouch-anal anastomosis.
  • A 56-yr-old woman was diagnosed as having familial adenomatous polyposis.
  • Endoscopic biopsies revealed adenocarcinoma at the ileal pouch.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / surgery. Colonic Pouches / pathology. Colorectal Neoplasms / diagnosis. Proctocolectomy, Restorative

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Nov;47(5):732-4 [11034594.001]
  • [Cites] Med Princ Pract. 2006;15(1):83-6 [16340235.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):487-99 [11330575.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):275-81 [11487537.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1714-5 [11711749.001]
  • [Cites] Int J Colorectal Dis. 2002 Mar;17(2):92-7 [12014427.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):6-13 [12544515.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):156-9 [12576887.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Colorectal Dis. 2003 Nov;5(6):592-4 [14617250.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):530-4 [14978621.001]
  • [Cites] Dis Colon Rectum. 1983 Dec;26(12):768-71 [6641457.001]
  • [Cites] Ann Surg. 1989 Sep;210(3):268-71; discussion 272-3 [2549890.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):90-5; discussion 95-6 [1987862.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):824-8 [8055729.001]
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1281-5 [7995159.001]
  • [Cites] Gut. 1994 Dec;35(12):1721-7 [7829009.001]
  • [Cites] Gastroenterology. 1995 Oct;109(4):1090-7 [7557073.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):506 [8665242.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):995-9 [8712299.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1487-92 [9136826.001]
  • [Cites] Indian J Cancer. 1997 Mar;34(1):16-9 [9491657.001]
  • [Cites] Int J Colorectal Dis. 1998;13(5-6):196-207 [9870162.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):695-702 [15862266.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):816-23 [15747076.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • (PMID = 19795007.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2752792
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenomatous Polyposis Coli / Ileal Pouches
  •  go-up   go-down


84. Leroy-Dudal J, Heyman L, Gauduchon P, Carreiras F: Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity. Cell Biol Int; 2005 Jun;29(6):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity.
  • To investigate adhesive events underlying this process, we used an in vitro model of cocultures between the IGROV1 human ovarian adenocarcinoma cell line and human umbilical vein endothelial cells (HUVECs).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914035.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Vitronectin; 0 / von Willebrand Factor
  •  go-up   go-down


85. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC: Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol; 2010 May 10;28(14):2445-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma.
  • PURPOSE: Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body mass index (BMI), and tobacco smoking have been individually associated with esophageal adenocarcinoma (EA) development.
  • In individuals with reflux symptoms, CART analysis indicated that strongest interaction was among variant genotypes of IL1B + 3954C>T and BAT3S625P, higher BMI, and smoking (odds ratio [OR], 5.76; 95% CI, 2.48 to 13.38), a finding independently found using MDR analysis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1801-6 [15330922.001]
  • [Cites] J Clin Epidemiol. 1995 Dec;48(12):1503-10 [8543964.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Int Immunopharmacol. 2005 Jul;5(7-8):1113-30 [15914317.001]
  • [Cites] J Med Genet. 2005 Jun;42(6):479-84 [15937082.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):967-74 [16186185.001]
  • [Cites] Genetics. 2005 Oct;171(2):783-90 [15956674.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2481-6 [16284367.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Am J Hum Genet. 2006 Mar;78(3):464-79 [16465622.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):347-9 [16574550.001]
  • [Cites] Genome Res. 2006 Jun;16(6):693-701 [16741161.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Aug 15;174(4):428-36 [16709937.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):1939-45 [16606631.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):1067-73 [17183065.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2160-5 [17728339.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3230-6 [18483392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1470-9 [18559563.001]
  • [Cites] Infect Immun. 2008 Aug;76(8):3725-34 [18541658.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Mayo Clin Proc. 2008 Oct;83(10):1087-94 [18828967.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2147-52 [18757527.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2330-4 [18780893.001]
  • [Cites] Am J Public Health. 2009 Feb;99(2):348-54 [19059868.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):75-91, viii [19327568.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1363-7 [19520791.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Genet Epidemiol. 2000 Dec;19(4):323-32 [11108642.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] Am J Epidemiol. 2002 Mar 1;155(5):478-84 [11867360.001]
  • [Cites] Genet Epidemiol. 2003 Feb;24(2):150-7 [12548676.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4327-30 [12907599.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6 [15240787.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • (PMID = 20385987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109193; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / R03 CA110822; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA110822; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / R01 CA109193; United States / NCI NIH HHS / CA / CA074386
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881724
  •  go-up   go-down


86. Kwon HJ, Kim JH, Bae JM, Cho NY, Kim TY, Kang GH: DNA methylation changes in ex-adenoma carcinoma of the large intestine. Virchows Arch; 2010 Oct;457(4):433-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation changes in ex-adenoma carcinoma of the large intestine.
  • Ex-adenoma carcinoma (EAC) is a carcinoma with contiguous adenoma element in its vicinity which provides a morphological evidence for adenoma-carcinoma sequence.
  • Twenty-two cases of cancers had contiguous tubulovillous adenomas and 17 cases had contiguous tubular adenomas.
  • Regardless of CIMP markers or nonrelated markers, a significant increase in the number of methylated genes was found from normal mucosa to adenoma, whereas no increase was found from adenoma to carcinoma.
  • Both ALU and LINE-1 showed a significant decrease of methylation levels from normal mucosa to adenoma (p < 0.05), but there is no difference between adenoma and cancer.
  • However, SAT2 methylation level exhibited a stepwise decrease from normal mucosa to adenoma to cancer.
  • Our findings suggest that morphological progression from traditional adenoma to carcinoma does not appear to be accompanied by increases in promoter CpG island hypermethylation or repetitive DNA hypomethylation, except for SAT2 hypomethylation which showed continuous progression during multistep carcinogenesis.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Colorectal Neoplasms / genetics. CpG Islands. DNA Methylation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2006 Aug;49(2):121-31 [16879389.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6005-13 [18829479.001]
  • [Cites] Curr Biol. 1999 Jan 28;9(2):R62-5 [10021355.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):854-65 [10982779.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):209-17 [16645207.001]
  • [Cites] Gastroenterology. 2009 Apr;136(4):1242-50 [19186181.001]
  • [Cites] Virchows Arch. 2009 Oct;455(4):343-51 [19763613.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1129-35 [11549606.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] Gut. 1996 Sep;39(3):434-8 [8949650.001]
  • [Cites] Oncogene. 2010 Mar 18;29(11):1653-62 [19966864.001]
  • [Cites] Mol Cancer Res. 2007 May;5(5):461-71 [17510312.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Nucleic Acids Res. 2005 Dec 02;33(21):6823-36 [16326863.001]
  • [Cites] Cancer. 2010 Oct 1;116(19):4495-501 [20572039.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):172-80 [19429481.001]
  • [Cites] Mol Cancer. 2008 Dec 31;7:94 [19117505.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):38-47 [19733896.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):781-9 [16708352.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):812-20 [19188151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1041-9 [19336559.001]
  • [Cites] Yonsei Med J. 2009 Jun 30;50(3):309-21 [19568590.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):21-33 [20028768.001]
  • [Cites] J Pathol. 2007 Feb;211(3):269-77 [17139617.001]
  • [Cites] Genes Dev. 2007 Dec 1;21(23):3110-22 [18056424.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12 ):1491-501 [17122504.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):305-14 [17591929.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1361-71 [12651628.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1922-9 [17278092.001]
  • (PMID = 20711609.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


87. Wei M, Morimura K, Wanibuchi H, Shen J, Salim EI, Moku M, Hakoi K, Fukushima S: JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats. Int J Cancer; 2005 Jan 20;113(3):354-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
  • Forty weeks after the start of the experiment, administration of 150 ppm JTE-522 during both initiation and postinitiation stages significantly inhibited the incidences of tubular adenocarcinomas and total carcinomas, as well as total tumors in the colon.
  • The inhibitory effect of JTE-522 was most prominent for tubular adenocarcinomas, but was not observed in the nontubular carcinomas (signet-ring cell and mucinous carcinomas).
  • Almost equal inhibitory effects on tubular adenocarcinomas were also observed in the rats given 150 ppm JTE-522 during the postinitiation stage, suggesting that its major anticancer action is at the postinitiation phase.
  • However, JTE-522 had no effect on the size or invasive extent of tubular adenocarcinomas.
  • Furthermore, microarray analyses revealed that JTE-522 had no effect on gene expression levels in DMH-induced tubular adenocarcinomas.
  • These findings suggest that JTE-522 possesses chemopreventive activity against induction but not progression of tubular adenocarcinomas in rat colon.
  • In view of the significant inhibitory effects of JTE-522 on ACF, its major anticancer action may occur in the postinitiation stage but before the malignant conversion stage of DMH-induced colon carcinogenesis.
  • [MeSH-major] 1,2-Dimethylhydrazine / toxicity. Adenocarcinoma / prevention & control. Benzenesulfonates / therapeutic use. Carcinogens / toxicity. Colonic Neoplasms / prevention & control. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors. Oxazoles / therapeutic use
  • [MeSH-minor] Adenoma / chemically induced. Adenoma / enzymology. Adenoma / prevention & control. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Progression. Gene Expression Profiling. Male. Oligonucleotide Array Sequence Analysis. Prostaglandin-Endoperoxide Synthases / metabolism. Rats. Rats, Inbred F344

  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455344.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Benzenesulfonates; 0 / Biomarkers, Tumor; 0 / Carcinogens; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Oxazoles; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


88. Di Giorgio A, Alfieri S, Rotondi F, Prete F, Di Miceli D, Ridolfini MP, Rosa F, Covino M, Doglietto GB: Pancreatoduodenectomy for tumors of Vater's ampulla: report on 94 consecutive patients. World J Surg; 2005 Apr;29(4):513-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluation of prognostic factors of adenocarcinoma of Vater's ampulla is still a matter of debate.
  • A total of 94 consecutive patients with ampullary carcinoma or adenoma with severe dysplasia were managed from 1981 to 2002.
  • Pancreatoduodenectomy is the treatment of choice for ampullary carcinoma and adenomas with high-grade dysplasia, with a good chance of long-term survival.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] World J Surg. 2002 Jun;26(6):709-14 [12053224.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):102-6; discussion 106-7 [7740792.001]
  • [Cites] Am Surg. 1996 Mar;62(3):197-202 [8607578.001]
  • [Cites] Ann Surg. 1982 Feb;195(2):152-7 [7055391.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1973-9 [10430380.001]
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1043-8 [10551754.001]
  • [Cites] HPB Surg. 2000;11(5):325-30; discussion 330-1 [10674748.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Feb;8(2):139-44 [8723418.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):1012-6 [9240155.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] J Am Coll Surg. 1994 Oct;179(4):462-4 [7921398.001]
  • [Cites] Arch Surg. 2001 Mar;136(3):343-7 [11231859.001]
  • [Cites] Ann Surg. 1987 Nov;206(5):572-7 [3314748.001]
  • [Cites] Ann Surg. 1977 Jan;185(1):52-7 [831636.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):632-7 [7487210.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jan;12(1):75-9 [10656214.001]
  • [Cites] Gut. 1981 Dec;22(12):1031-4 [7319287.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] HPB Surg. 1998;11(1):1-11 [9830575.001]
  • (PMID = 15776300.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Yoneda M, Suzuki T, Nakamura T, Ajima R, Yoshida Y, Kakuta S, Katsuko S, Iwakura Y, Shibutani M, Mitsumori K, Yokota J, Yamamoto T: Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma. Cancer Sci; 2009 Feb;100(2):225-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma.
  • We further show that ana expression is reduced in 97% of the human lung cancer cell lines examined (61/63) and 86% of clinical samples from lung adenocarcinoma patients (36/42).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Proteins / metabolism. Proteins / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068083.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BTG3 protein, human; 0 / Btg3 protein, mouse; 0 / Plasminogen Activator Inhibitor 1; 0 / Proteins; 0 / RNA, Messenger; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


90. Dib N, Benhammou A, Meziane M, Harmouch A, Nazih N, Essakali L, Kzadri M, Sefiani S: [Papillary adenocarcinoma on ectopic thyroid tissue]. Ann Otolaryngol Chir Cervicofac; 2009 Apr;126(2):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary adenocarcinoma on ectopic thyroid tissue].
  • OBJECTIVES: To report a case of papillary adenocarcinoma occurring on ectopic thyroid tissue in the hyoid bone region.
  • The pathologic study suggested a papillary adenocarcinoma on ectopic thyroid tissue.
  • CONCLUSIONS: Papillary adenocarcinoma on ectopic thyroid is a very rare situation.
  • Its diagnosis is histological.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Choristoma / pathology. Hyoid Bone / pathology. Thyroid Gland. Tongue Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Thyroidectomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296927.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Liu SH, Tsay SH: Coexistence of large cell neuroendocrine carcinoma and adenocarcinoma of the ampulla of vater. J Chin Med Assoc; 2008 Oct;71(10):536-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of large cell neuroendocrine carcinoma and adenocarcinoma of the ampulla of vater.
  • We report a case of coexisting poorly differentiated endocrine carcinoma and conventional adenocarcinoma in the ampulla of Vater.
  • After thorough microscopic examination of the ampulla of Vater, we incidentally found another conventional adenocarcinoma on the inner side of the duodenal papilla, and the tumor collided with the aforementioned carcinoma.
  • The association of neuroendocrine tumor and adenocarcinoma has been reported in a few case reports and a small series.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Carcinoma, Large Cell / pathology. Common Bile Duct Neoplasms / pathology. Neuroendocrine Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955190.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 16
  •  go-up   go-down


92. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A; 2006 Jul 18;103(29):10991-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
  • Adenocarcinomas of the prostate can be categorized into tumor grades based on the extent to which the cancers histologically resemble normal prostate glands.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):477-8 [10757394.001]
  • [Cites] Pac Symp Biocomput. 2000;:455-66 [10902193.001]
  • [Cites] Oncogene. 2000 Aug 24;19(36):4159-69 [10962577.001]
  • [Cites] Urology. 2000 Nov 1;56(5):823-7 [11068310.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22278-86 [11294878.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5692-6 [11479199.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jan;80(1):13-23 [11867260.001]
  • [Cites] Lab Invest. 2002 May;82(5):629-37 [12004003.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):363-71 [12112525.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3206-12 [12149292.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):20-9 [12640657.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3418-24 [12960131.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5376-80 [14500371.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):415-22 [14499674.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4914-25 [14581366.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2560-5 [14669274.001]
  • [Cites] Neurotoxicology. 2004 Jan;25(1-2):317-24 [14697906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Prostate. 2004 May 15;59(3):337-49 [15042610.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6082-90 [15342391.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] JAMA. 1995 Aug 23-30;274(8):626-31 [7637143.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):683-7 [8698312.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):168-75 [9428494.001]
  • [Cites] Prostate. 1999 May;39(2):135-48 [10221570.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1251-6 [15502842.001]
  • [Cites] Cell. 2005 Jun 3;121(5):667-70 [15935753.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4281-92 [15806160.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):215-21; Discussion 221-3 [15992991.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53 [16145045.001]
  • [CommentIn] Eur Urol. 2007 Mar;51(3):851-2 [17421063.001]
  • (PMID = 16829574.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE5132
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK065204; United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / P01 CA085859; United States / NCI NIH HHS / CA / P50CA97186; United States / NCI NIH HHS / CA / P01CA85859; United States / NIDDK NIH HHS / DK / DK65204
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1544162
  •  go-up   go-down


93. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K: Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol; 2010 Aug;5(8):1136-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung.
  • INTRODUCTION: The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene is one of the most intriguing recent discoveries in the field of lung cancer research, and they are more commonly found in adenocarcinoma occurring in females, never/light smokers, and East Asian patients.
  • METHODS: This study evaluated the medical records of 437 patients with adenocarcinoma of the lung who underwent a surgical resection.
  • In females, the incidences of EGFR mutation were 61.0% and 41.7% in HLA-A2 (+) and A2 (-) patients with adenocarcinoma of the lung, respectively (p = 0.008).
  • CONCLUSIONS: EGFR: mutations are associated with HLA-A2 in female patients with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group / genetics. Histocompatibility Antigens / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20548248.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 9007-49-2 / DNA; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


94. Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, Ayazi S, Leers JM, Lipham JC, Hagen JA, DeMeester TR: Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg; 2007 Oct;246(4):665-71; discussion 671-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia.
  • OBJECTIVE: Our aim was to compare outcome of vagal-sparing esophagectomy with transhiatal and en bloc esophagectomy in patients with intramucosal adenocarcinoma or high-grade dysplasia.
  • SUMMARY BACKGROUND DATA: Intramucosal adenocarcinoma and high grade dysplasia have a low likelihood of lymphatic or systemic metastases and esophagectomy is curative in most patients.
  • A vagal-sparing esophagectomy offers the advantages of complete disease removal with the potential for reduced morbidity and a better functional outcome.
  • METHOD: Retrospective review of outcome in patients with intramucosal adenocarcinoma or high grade dysplasia that had a vagal-sparing (n=49), transhiatal (n=39) or en bloc (n=21) esophagectomy.
  • CONCLUSION: Survival with intramucosal adenocarcinoma or Barrett's with high-grade dysplasia is independent of the type of resection.
  • Consequently a vagal-sparing esophagectomy is the preferred procedure for patients with intramucosal adenocarcinoma or high grade dysplasia.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Barrett Esophagus / surgery. Body Weight / physiology. Diarrhea / prevention & control. Dumping Syndrome / prevention & control. Esophageal Neoplasms / surgery. Esophagus / physiopathology. Female. Follow-Up Studies. Hospitalization. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Postoperative Complications / prevention & control. Retrospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):302-3 [18431373.001]
  • (PMID = 17893503.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S: Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J; 2008 Dec 31;49(6):1046-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma.
  • We present our preliminary findings from 4 cases of liver metastasis from gastric adenocarcinomas treated using radiofrequency ablation (RFA).
  • Although this study was limited to a few cases and had a short follow-up duration, our findings suggest that RFA may provide an alternative treatment modality for liver metastasis resulting from gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin Biol. 1999 Nov;23(11):1128-33 [10651531.001]
  • [Cites] Surg Gynecol Obstet. 1989 Oct;169(4):371-85 [2476864.001]
  • [Cites] Surg Today. 2000;30(11):1041-5 [11110405.001]
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1062-5 [12143202.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):682-9 [12399057.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):356-9 [6158880.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):897-900 [9222711.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1737-9 [15553699.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Am Surg. 2005 Feb;71(2):95-9 [16022005.001]
  • [Cites] Ann Ital Chir. 2005 Jan-Feb;76(1):39-41 [16035670.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):265-72 [16183480.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1747-51 [16371545.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • (PMID = 19108032.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628018
  •  go-up   go-down


96. Paduch R, Kandefer-Szerszeń M, Szuster-Ciesielska A, Plewka K: Transforming growth factor-beta1 modulates metalloproteinase-2 and -9, nitric oxide, RhoA and alpha-smooth muscle actin expression in colon adenocarcinoma cells. Cell Biol Int; 2010 Feb;34(2):213-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1 modulates metalloproteinase-2 and -9, nitric oxide, RhoA and alpha-smooth muscle actin expression in colon adenocarcinoma cells.
  • In order to evaluate the role of TGF-beta1 (transforming growth factor-beta1) and small G protein RhoA in tumour progression, the influence of TGF-beta1 treatment or RhoA-associated kinase inhibitor on the production of NO (nitric oxide) and MMP-2 and MMP-9 (metalloproteinases-2 and -9) was analysed in three human colon adenocarcinoma cell lines (HT29, LS180, SW948) representing different stages of tumour development.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Transforming Growth Factor beta1 / pharmacology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947919.001).
  • [ISSN] 1095-8355
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Amides; 0 / Pyridines; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta1; 138381-45-0 / Y 27632; 31C4KY9ESH / Nitric Oxide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


97. Zhang Q, Zhao XH, Wang ZJ: Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol; 2008 Jun;46(6):2042-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis.
  • In our study, cytotoxic effects of structurally related flavones and flavonols on a human oesophageal adenocarcinoma cell line (OE33) were compared, and the molecular mechanisms responsible for their cytotoxic effects were explored.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Cell Division / drug effects. Esophageal Neoplasms / drug therapy. Flavones / pharmacology. Flavonols / pharmacology. G2 Phase / drug effects
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. DNA Fragmentation / drug effects. DNA Primers. Humans. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tetrazolium Salts. Thiazoles

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331776.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / Flavones; 0 / Flavonols; 0 / RNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  •  go-up   go-down


98. Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B: Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch; 2009 Jun;454(6):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.
  • Our objective was to study the gross genomic alterations in serous borderline tumors and serous adenocarcinomas of the ovary.
  • A retrospective analysis of 245 serous borderline tumors and 62 serous adenocarcinomas from 249 patients was performed using high-resolution image cytometric DNA ploidy analysis.
  • Grades 2 and 3 serous adenocarcinomas were more often (80%) nondiploid, mostly with DNA index exceeding 1.4.
  • Grade 1 serous adenocarcinomas were an intermediate group, more similar to serous borderline tumors.
  • The S-phase fraction increased from serous borderline tumors (mean = 0.6%) through grade 1 serous adenocarcinomas (mean = 2.8%), being highest in grades 2 and 3 adenocarcinomas (mean = 6.8%).
  • Our findings support the hypothesis that serous borderline tumors and grades 2 and 3 serous adenocarcinomas are genomically different lesions, with grade 1 serous adenocarcinomas being an intermediate group more close to borderline tumors.
  • [MeSH-major] Aneuploidy. Cystadenocarcinoma, Serous / genetics. DNA, Neoplasm / analysis. Image Cytometry / methods. Ovarian Neoplasms / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):35-40 [19047910.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4456-60 [8402612.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):103-8 [16737908.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):307-15 [10398423.001]
  • [Cites] Int J Gynecol Cancer. 1993 Nov;3(6):349-358 [11578368.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):794-802 [8756374.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 ):3947-51 [8508360.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):152-60 [1606537.001]
  • [Cites] Cancer Res. 1984 May;44(5):2198-202 [6713406.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Jun;25(3):139-45 [12882085.001]
  • [Cites] Int J Gynecol Cancer. 2000 Nov;10(6):477-487 [11240718.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):95-8 [8976364.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):632-41 [12152163.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):59-72 [12742157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13692-7 [9811862.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(6):829-36 [3094243.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1494-500 [14504048.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 15;146(2):145-53 [14553949.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1494-500 [8608534.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):59-66 [8690293.001]
  • [Cites] Cancer. 1992 May 15;69(10):2510-4 [1568173.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):18-23 [12547152.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2005-10 [3167812.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 19421773.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


99. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


100. Tsuta K, Ishii G, Nitadori J, Murata Y, Kodama T, Nagai K, Ochiai A: Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol; 2006 May;209(1):78-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin.
  • The latest World Health Organization (WHO) classification divides adenocarcinoma mainly into adenocarcinoma mixed subtypes, acinar adenocarcinoma, papillary adenocarcinoma, bronchioloalveolar carcinoma, and solid adenocarcinoma with mucin production, and it mentions several variants, including fetal adenocarcinoma, mucinous ("colloid") adenocarcinoma, mucinous cystadenocarcinoma, signet-ring adenocarcinoma, and clear cell adenocarcinoma.
  • In general, the mucin-producing adenocarcinoma of the lung comprises signet-ring cell carcinoma (SRCC), solid adenocarcinoma with mucin production (SA), and mucinous bronchioloalveolar carcinoma (m-BAC), mucinous ("colloid") adenocarcinomas and/or mucinous cystadenocarcinoma, and mucoepidermoid carcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Lung Neoplasms / immunology. Mucins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / immunology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / immunology. Carcinoma, Signet Ring Cell / metabolism. Humans. Immunoenzyme Techniques. Immunophenotyping. Protein Array Analysis / methods






Advertisement